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ABSTRACT 
In an effort to achieve replicative immortality, human cancer cells must avoid the 
constant telomere attrition that accompanies DNA replication. Cancer cells accomplish 
this by employing mechanisms to lengthen their telomeres. Approximately 10 percent of 
all cancers utilize the Alternative Lengthening of Telomeres (ALT) pathway to maintain 
telomere length. Although ALT is known to rely on homologous recombination between 
two telomeric sequences, the exact mechanism and regulators of the ALT pathway 
remain elusive. 
As common fragile sites, telomeres pose a challenge to the replication machinery. 
This replication challenge is exacerbated in ALT cells due to defects in nucleosome 
assembly, suggesting the importance of managing replication stress at telomeres in these 
cells. ATR (ataxia telangiectasia and Rad3-related) is an important kinase in the response 
to replication stress. The work in this thesis demonstrates that ATR is also a key mediator 
of ALT activity. Due to the highly recombinogenic state of ALT telomeres, these cells 
depend on ATR activity. In fact, we illustrate that small molecule inhibition and siRNA 
mediated loss of ATR disrupts ALT activity and promotes cell death specifically in ALT 
  ix 
positive cancer cells. Although we establish ATR as a critical regulator and effective 
therapeutic target in ALT cancers, the exact mechanism of ATR in this pathway remains 
elusive. Recently, the chromatin remodeling enzyme SMARCAL1 (SWI/SNF-related, 
matrix-associated, actin-dependent regulator of chromatin subfamily A-like protein 1) 
was identified as one of the most abundant proteins bound to sites of replication stress. 
We demonstrate by combined immunofluorescence-FISH and chromatin 
immunoprecipitation that SMARCAL1 associates with ALT telomeres to resolve 
replication stress and maintain telomere stability. Specifically, we illustrate that siRNA 
mediated loss of SMARCAL1 in ALT cancer cells results in persistently stalled 
replication forks that collapse into DNA double strand breaks, which promotes the 
formation of chromosome fusions. Ultimately, we illustrate that loss of SMARCAL1 in 
ALT cancer cells promotes genomic instability through telomere dysfunction. 
Although great strides have been made in defining the ALT mechanism, the 
drivers of this pathway remain elusive. These studies highlight the importance of 
replication stress in both activation and maintenance of the ALT pathway. Our data 
demonstrate chronic replication stress as a key feature at ALT telomeres. Importantly, we 
were able to exploit this feature to identify a novel therapeutic avenue for ALT positive 
cancers.   
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CHAPTER ONE: INTRODUCTION 
Section One: Telomeres 
The linear nature of eukaryotic chromosomes presents two inherent challenges for 
the cell; one challenge centers on replication. The ‘end-replication problem’ results from 
the shortcomings of semi-conservative DNA replication. DNA polymerases are limited 
by unidirectional synthesis of nucleotides and the requirement of a primer to initiate 
synthesis. These characteristics prevent the complete replication of linear chromosome 
ends, resulting in the loss of DNA. With each passage through the cell cycle the 
chromosomes become shorter, and important protein coding information is lost. This 
deficiency in replication is termed the ‘end-replication problem’.1,2 In order to prevent the 
loss of valuable genetic information the cell must find a way to preserve its chromosome 
ends. Telomeres present a solution to this issue. Telomeres are repetitive tracts of DNA, 
comprised of the hexanucleotide repeat ‘TTAGGG,’ that cap and protect the ends of 
chromosomes (Figure 1-1A). They include a double-stranded tract spanning 10-15 
kilobases and a single-stranded 3’ G-rich overhang, which ranges from 50-500 
nucleotides.3,4 Telomeres temporarily solve the ‘end-replication problem’ by serving as a 
buffer to the chromosome end attrition that occurs as a result of progression through the 
cell cycle. Therefore, although telomeres at the chromosome ends become shorter, the 
genes are unaffected.  
The second challenge presented by linear chromosome ends centers on protection. 
The observation that linear DNA cannot remain stable when introduced into eukaryotic 
cells shaped the idea of the ‘end-protection problem’.5,6 When the cell detects a break in 
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the DNA, it elicits a DNA damage response (DDR).  This response results in a repair 
mechanism that mends broken chromosomes, such as homology directed repair (HDR) 
and non-homologous end joining (NHEJ). It was demonstrated that exogenous linear 
DNA undergoes a DNA repair pathway when introduced to cells.5 These findings posed a 
critical question: Why were these damage pathways not activated by linear chromosome 
ends? If the cell were to recognize its own telomere ends as sites of damage, the resulting 
repair mechanisms would induce major genomic instability. Therefore the ‘end-
protection problem’ must be solved to preserve genomic integrity. The cell requires a 
mechanism to distinguish between its own chromosome ends and breaks in the DNA to 
solve the ‘end-protection problem’. This challenge is answered by the six protein subunit 
complex, shelterin. Shelterin is a protective complex that binds to telomeres and shields 
ends from being recognized as sites of damage. Additionally, shelterin is required for t-
loop formation. The end of the telomere forms a lariat structure, termed the t-loop (Figure 
1-1B).7 The t-loop forms when the 3’ overhang invades the duplex region, and the t-loop 
assists in the protection of chromosome ends from aberrant repair mechanisms.8  
Shelterin 
Shelterin is a six-protein subunit complex that binds to telomeres (Figure 1-1C). 
Shelterin protects telomere ends by distinguishing a cell’s natural chromosome ends from 
DNA breaks, thereby repressing DNA repair actions. Two of the components of shelterin, 
telomeric repeat binding factor 1 (TRF1) and telomeric repeat binding factor 2 (TRF2), 
bind with sequence specificity to the double stranded ‘TTAGGG’ repeats at the 
telomere.8,9 TRF1 and TRF2 both share a TRF homology (TRFH) domain and a c-
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terminal SANT/myb DNA binding domain, but these two proteins differ in their extreme 
N-terminal regions.8 TRF1 contains an acidic N-terminal domain, whereas TRF2 has a 
glycine/ arginine rich (GAR) domain. It is hypothesized that these differences allow for 
the recruitment of different shelterin accessory factors to the telomeres. Although both 
proteins bind DNA as homodimers, TRF1 and TRF2 do not interact directly with one 
another. These two factors are responsible for recruiting the remaining four components 
of SHELTERIN: human repressor activator protein 1 (RAP1), TRF2- and TRF1- 
Interacting Nuclear protein 2 (TIN2), TPP1 (formerly known as TINT1, PTOP, or PIP1), 
and Protection of Telomeres 1 (POT1). RAP1 is a binding partner of TRF2. Given that 
RAP1 lacks DNA binding activity, its association with TRF2 is necessary for RAP1 
localization to the telomere.10,11 TIN2 is a central component of shelterin; Able to bind 
TRF1, TRF2, and TPP1, TIN2 bridges non-interacting components of shelterin.12–16 
Consequently, loss of TIN2 destabilizes shelterin. TIN2 recruits TPP1 and POT1, which 
bind telomeres as a heterodimer. Although POT1 can also independently bind the single 
stranded telomeric overhangs present at the 3’ end, interaction with TPP1 enhances POT1 
affinity for the single stranded telomeric DNA.8 Loss of POT1 leads to telomere 
dysfunction and a loss of ssDNA. In fact, loss of almost any of the Shelterin components 
leads to telomere dysfunction and results in activation of a DNA damage response. 
Therefore, shelterin is necessary to protect the telomere ends to ensure genomic stability. 
Structural complexities 
Although telomeres serve to protect chromosome ends from attrition and aberrant 
repair, they also pose a problem for replication. Despite aiding in chromosome end 
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protection, the t-loop creates a natural barrier for the DNA replication machinery.17–21 
Additionally, the repetitive nature of telomeres results in the formation of secondary 
structures that further hinder replication.22,23 These structural complexities result in 
frequent replication fork stalling and chromosome breakage, which highlight telomeres as 
common fragile sites (CFS).24–26 Therefore, determining both the role and regulation of 
replication stress at telomeric DNA is essential for our understanding of genomic 
instability.   
Section Two: Telomere Maintenance Mechanisms 
Cancer cells require unlimited replicative potential for tumor formation.27 To 
achieve this, cells must overcome two critical barriers: senescence and crisis. Most cells 
have a limited number of divisions before they enter senescence, a state where the cells 
are still metabolically active but are no longer able to replicate. If cells are able to 
circumvent this barrier, they enter crisis. Crisis, a stage involving cell death, is triggered 
by telomere erosion. Gradual telomere attrition occurs with each cell cycle, and 
eventually the telomeres are too short to afford chromosome end protection. As a result, 
end-to-end fusions and other chromosomal aberrations occur and threaten the viability of 
the cell. Cells that succeed in overcoming crisis and achieve unlimited replicative 
potential are termed immortal. Overcoming both barriers requires cancer cells to promote 
telomere elongation. The majority of cancer cells accomplish this by employing one of 
two known telomere maintenance mechanisms (TMM) – telomerase or the Alternative 
Lengthening of Telomeres Pathway (ALT).   
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Figure 1-1. Structure of the telomere.* (A) Double stranded telomeric region consisting of TTAGGG 
repeats with a 3’ G-rich overhang depicted in red. (B) Telomeric loop (t-loop) is formed when the single 
stranded overhang invades the duplex region of the telomere. (C) The shelterin complex is a six protein 
subunit complex composed of TRF1, TRF2, TIN2, TPP1, POT1, and RAP1. (D) Shelterin binds 
progressively along the telomere.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted from: Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and 
implications. Nat Rev Genet. 2010;11(5):319-330. doi:10.1038/nrg2763. 
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Telomerase 
Approximately 85% of all human cancers reactivate telomerase, an enzyme that 
elongates telomeres. Telomerase is strongly expressed in early embryogenesis, but this 
expression is lost during cellular differentiation.28 Thus, most normal somatic cells carry 
all of the genes for telomerase but do not express them at levels significant enough for 
efficient enzymatic activity. On rare occasions, cells overcome crisis by de-repressing the 
genes encoding telomerase. This phenomenon is seen in cell culture, and it is 
hypothesized that a similar event occurs in vivo when pre-neoplastic cells escape crisis 
and become immortal.28 Telomerase is composed of two central components. One 
subunit is a reverse transcriptase TERT, which transcribes DNA from an RNA 
template.29–31 Conveniently, the RNA template TERC is the second key component. 
Experiments reintroducing human TERT cDNA to pre-crisis cells, which were then able 
to circumvent crisis, demonstrated that these cells typically express high levels of TERC 
but not TERT.32 Given that most normal somatic cells do not express telomerase, this 
mechanism is an attractive target in the treatment of cancer. Clinical trials assessing 
telomerase-targeted therapies are currently underway, however, these therapies will be 
ineffective in cancers that do not utilize telomerase.31  
The Alternative Lengthening of Telomeres Pathway 
The remaining 10-15% of cancers promote telomere elongation by employing the 
Alternative Lengthening of Telomeres pathway (ALT) (Figure 1-2A).29,31 ALT occurs 
across tissue types, but there is a particularly high prevalence of ALT in certain subsets of 
cancer, including some sarcomas (i.e., osteosarcomas and liposarcomas) and certain 
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central nervous system tumors (i.e., glioblastoma and astrocytoma).33 ALT may prevail in 
certain sarcomas because of their mesenchymal origin.34 Many hypothesize that 
mesenchymal cells repress telomerase more tightly because these cells  have slower cell 
turnover and consequently less telomere shortening.34 ALT positive cancers are defined 
by the ability to maintain their telomere length after many population doublings in the 
absence of telomerase activity.33 Therefore, ALT may have a greater probability of being 
activated in mesenchymal cells, where telomerase repression is stronger. ALT is a 
recombination based mechanism, but the exact mechanisms driving and maintaining ALT 
remain elusive. Despite these gaps in knowledge, great strides have been made in 
identifying components of the ALT pathway.  
ALT activity is detected through several key hallmarks and phenotypes. One of 
the most notable phenotypes of ALT cells is the presence of a large amount of 
extrachromosomal telomeric DNA (ECTR).35,36 These ECTR can manifest as double-
stranded telomeric circles (t-circles), mostly single-stranded circles (c-circles), or short 
stretches of double-stranded linear telomeric repeats (Figure 1-2B).33 The exact origin 
and function of ECTR is not fully understood. However, these ECTR are proposed to be 
recombination byproducts, substrates for recombination, the products of telomere 
trimming, or all the above.33  
ECTR and the telomeres themselves colocalize in a small fraction of 
promyelocytic leukemia bodies (PML).29 PML bodies are nuclear bodies proposed to 
function in various cellular processes. Although PML bodies are present in most cells, 
only in ALT cells do PML bodies co-localize with telomeric DNA, which is why they are 
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termed ALT-associated PML bodies (APB) (Figure 1-2C). In addition to telomeric DNA 
and the constitutive components of PML bodies such as PML and Sp100, APBs also 
contain proteins involved in recombination and repair.37,38 The precise function of APBs 
in the ALT pathway remains to be elucidated. Initial discovery of APBs found that a 
fraction of APB positive cells did not incorporate BrdU and displayed a senescent 
morphology.38 However, the association of APBs with senescence is thought to be a 
minor component of APB function, and more recent data suggests the possibility that 
APBs are functionally heterogeneous.29,37 One of the proposed roles of APBs is that they 
are simply a byproduct of the ALT pathway. Studies demonstrating the requirement of 
HP1 (heterochromatin protein 1) in the formation of APB support this notion.37,39 Given 
that HP1 is a marker of “closed” chromatin, it is likely that some fraction of APB are not 
sites of active telomere recombination. The most favored hypothesis proposes that APB 
play an integral role in the ALT mechanism.40–45 This hypothesis was indirectly 
supported by several studies demonstrating that inhibition of ALT resulted in substantial 
decreases in APBs.46–49 Furthermore, a recent study illustrated that telomeres cluster in 
PML bodies as a result of directed movement to initiate telomere synthesis.44 Therefore, 
it is likely that a subset of APBs are involved in active recombination of telomeres in 
ALT.   
ALT status in tumors correlates with mutations in or loss of the ATRX protein.50–
52 ATRX (Alpha Thalassemia/Mental Retardation Syndrome X-Linked) interacts with 
DAXX to form a chromatin-remodeling complex, which deposits the histone variant 
H3.3 at telomeres and other G-rich repetitive sequences.53–57 Its precise function remains 
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unknown, but reduced ATRX function increases the telomeric repeat containing RNA 
(TERRA).58 Although telomeres were previously thought to be transcriptionally silenced, 
it is now widely accepted that telomeres are transcribed by RNA polymerase II, resulting 
in the long noncoding RNA TERRA.58,59 The precise function of TERRA is still being 
established. However, it has been demonstrated to aid in regulation of telomere 
homeostasis and telomere function.59,60 
We have previously demonstrated that TERRA is cell cycle regulated and 
coordinates telomere replication and end protection.61 TERRA is responsible for 
sequestering hnRNPA1 (heterogeneous ribonucleoprotein A1) from telomeres, which 
allows for the binding of replication protein A (RPA) to single stranded DNA (ssDNA) at 
telomeres (Figure 1-2D). The presence of RPA subsequently promotes telomere 
replication. TERRA levels decrease as the cell progresses through S phase, which causes 
the release of hnRNPA1 and displacement of RPA. After the G2 phase, TERRA 
reaccumulates and resumes cyclical control of hnRNPA1, which is essential for the 
assembly of shelterin at telomeric DNA. Recently, we determined that the cell-cycle 
regulation of TERRA is impaired in ALT cells, which contain very high levels of 
TERRA transcript.49 Due to its increased presence, TERRA may serve an important role 
in the maintenance of the ALT pathway. 
Another hallmark of ALT cells is the extremely heterogeneous nature and overall 
size of their telomere lengths. Telomeres of ALT cells can measure more than 30kb long, 
as opposed to 5-10kb for telomerase positive cells. This trait coupled with the observation 
that telomere length in ALT cells can increase and decrease rapidly were the first 
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indications that ALT was potentially a recombination mediated mechanism.62 It is now 
widely accepted that ALT cells have a heightened frequency of recombination 
specifically at their telomeres, most often detected by telomere sister chromatid exchange 
events (TSCE).63 TSCE are recombination events that occur between telomeres using an 
adjacent source of telomeric DNA as a copy template for homology directed repair 
(Figure 2E).64 
Although there is a consensus that ALT cells rely on recombination, the exact 
mechanism of telomere elongation is unknown. Currently, there are two non-mutually 
exclusive mechanisms that are favored: the unequal T-SCE model and the homologous 
recombination-dependent DNA replication (HRDD) model.29 The increased frequency of 
T-SCE in ALT cells versus non-ALT cells gave rise to the unequal T-SCE model, which 
posits that one daughter cell has a lengthened telomere and greater proliferative capacity, 
while another daughter cell has a shortened telomere and less proliferative capacity 
(Figure 1-3A).65 For this mechanism to be viable long term, every lengthened telomere 
would have to be preferentially segregated into one daughter cell, while every shortened 
telomere was allotted to the other.66,67 The second model – HRDD – proposes that ALT 
telomere elongation results from recombination mediated synthesis of new telomeric 
DNA using an existing adjacent telomeric sequence (Figure 1-3B).34,64 This model results 
in a net increase of telomeric DNA, negating the need for a segregation mechanism. In 
this model, the template DNA can be sourced from another telomere, ECTR, or its own t-
loop.29,34,68 Recombination between non-sister telomeres or with ECTR in the HRDD  
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Figure 1-2. The ALT pathway is characterized by several key hallmarks.* (A) ECTR can manifest as 
T-circles (predominately double stranded) or C-circles (predominately single stranded) telomeric repeats. 
(B) Immunofluorescence images of an ALT positive U2OS cell stained for PML and TRF2 (a shelterin 
component and marker of telomeric DNA). (C) Schematic depicting the sequestration of hnRNP by 
TERRA to facilitate the switching of RPA and SHELTERIN. (D) Illustration of one possible T-SCE 
mechanism. A recombination event occurs between the telomeres of two sister chromatids, resulting in a 
long and short telomere.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted from references: 31, 44, 56, 159 
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model can also explain the heightened frequency of non-canonical repeats in proximal 
telomeric regions of ALT cells.69  
In addition to the canonical TTAGGG sequence, ALT telomeres have an increase 
in variant hexameric repeats including TCAGGG, TTCGGG, and GTAGGG.69,70 Variant 
repeats disrupt binding of the shelterin components TRF1 and TRF2, which bind to 
telomeres based on sequence specificity. Loss of TRF1 increases replication fork stalling 
and enhances telomere fragility.25,26 Moreover, TRF2 prevents the resolution of telomeric 
recombination intermediates.17,18 Not only do TRF1 and TRF2 afford the telomere 
protection against specific sources of stress, but they are also responsible for recruiting 
the remaining components of the telomere protection complex shelterin. Loss of shelterin 
binding, also known as telomere uncapping, results in telomere processing by multiple 
DNA damage response pathways, including ataxia telangiectasia mutated (ATM), ATM 
and Rad3-related (ATR), non-homologous end joining (NHEJ), and HR.71 Therefore, to 
gain further insight into the mechanisms that drive ALT, it is imperative to understand 
the role of the DNA damage response and its potential dysregulation at telomeres in 
ALT. 
Section Three: DNA Damage Response 
 Our genetic material constantly faces the threat of spontaneous damage from both 
endogenous and exogenous sources. In fact, it is estimated that every cell can experience 
as many as 105 spontaneous DNA insults per day.72 Endogenous lesions alone can result 
from various causes, including dNTP misincorporation, interconversion, loss, or 
modification of DNA bases, and breaks due to reactive oxygen species (ROS) produced 
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from normal cellular metabolism.73,74 Exogenous sources include environmental damage 
(i.e., ultra violet (UV) radiation from sunlight) or chemical agents, such as those used in 
chemotherapeutics. These sources of damage can cause various detrimental lesions, such 
as DNA crosslinks and strand breaks. These genetic insults not only compromise the 
ability to faithfully transmit our genetic material to offspring, but they also put our own 
health at risk, as defects in genome maintenance can cause a wide array of disorders, 
including cancer.75–78 To respond to this continuous threat and preserve genomic 
integrity, cells have established a DNA damage response (DDR) to identify and repair 
damaged genetic material.  
The DNA damage response (DDR) is a signal transduction pathway that 
recognizes sites of damage and promotes various pathways that share three common 
steps: damage sensing, signal transduction, and downstream effects. Ultimately, the DDR 
results in one of three generalized responses: DNA repair, cell cycle arrest, or apoptosis 
(Figure 1-4A). The DDR encompasses many complicated repair pathways, each designed 
to mend a particular subtype of damage. The work in this thesis focuses on the 
homologous recombination (HR) repair pathway as a response to double strand breaks 
(DSBs) and replication stress.  
Homologous Recombination Repair 
 HR repair typically occurs in late S and G2 phases of the cell cycle, when sister 
chromatids or homologous chromosomes are available.79 The HR repair of DSBs is 
initiated through the MRN (Mre11-RAD50-Nbs1) sensor complex, which detects the 
damage, stabilizes DNA ends, and prepares the initial steps of end resection essential for   
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Figure 1-3. Recombination mediated mechanisms of telomere elongation in ALT.* (A) The unequal T-
SCE model proposes that ALT telomeres recombine using a sister chromatid. This results in an unequal 
distribution of telomere length, requiring a non-random segregation mechanism to accompany it. (B) The 
HRDD model supports the notion that ALT telomeres  utilize homologous recombination mediated 
telomere synthesis which results in an overall net gain of telomeric DNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted from: Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and 
implications. Nat Rev Genet. 2010;11(5):319-330. doi:10.1038/nrg2763. 
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HR.80 Subsequently, ATM (ataxia telangiectasia mutated kinase), one of the DDR 
kinases, is activated. The DDR kinases – ATM, ATR (ATM and Rad3-related), and 
DNA-PK (DNA dependent protein kinase) – are members of the phosphatidylinositol 3-
kinase-like protein kinase (PIKKs) family and serve as the primary mediators of the 
DDR. ATM and ATR phosphorylate the histone γH2AX at serine 139 to propagate its 
spreading and promote signal amplification.81,82 In HR repair, ATM has many 
downstream targets including p53. ATM activates p53 to induce cell-cycle arrest, 
apoptosis, or senescence, depending on the extent of damage.83 Additionally, ATM is 
responsible for regulating CtIP, a nuclease that interacts with BRCA1 to facilitate end 
resection.84 
 DSB resection leads to the formation of 3’ ssDNA ends and accumulation of RPA 
(replication protein A), which specifically binds ssDNA. RPA, a heterotrimeric complex, 
is responsible for stabilizing ssDNA in both replication and repair by preventing the 
formation of abnormal secondary structures.85 RPA coated ssDNA (RPA—ssDNA) is a 
structure essential for the recruitment of ATR to sites of damage and replication stress.86 
The localization of ATR to RPA—ssDNA is dependent on the ATR co-factor ATRIP 
(ATR-interaction protein) (Figure 1-4B).87 ATRIP directly binds RPA, which facilitates 
the localization of ATR.88 Although RPA is required for ATR-ATRIP recruitment, it is 
not sufficient for ATR activation.89–92 Activation of ATR depends on the recruitment of 
TOPBP1 (topoisomerase-binding protein-1). This is accomplished by the RAD9-RAD1-
HUS1 (9-1-1) complex, which is loaded onto chromatin adjacent to ATR-ATRIP.93–95  
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Figure 1-4. DDR Pathways.* (A) General schematic illustrating progression of events of DNA damage 
response pathways. (B) ATR activation schematic of replication stress, beginning with RPA—ssDNA 
recruitment of ATR/ATRIP. Subsequent recruitment of the activating factor TOPBP1 is followed by 
downstream signaling which manifests primarily through CHK1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted from Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol 
Cell Biol. 2008;9(8):616-627. doi:10.1038/nrm2450. 
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Once activated, ATR is responsible for initiating a phosphorylation cascade both 
away from and at the site of damage. ATR phosphorylates and activates the downstream 
soluble effector kinase CHK1.96 Once activated, CHK1 is released from chromatin to 
phosphorylate its downstream targets.97 CHK1 mediates numerous processes important in 
replication and repair, namely cell-cycle arrest and RAD51 recruitment to sites of 
damage.74,98,99 RAD51 filament assembly at RPA coated ssDNA facilitates strand 
invasion into homologous sequences, ultimately resulting in HR repair of the DSB lesion 
(Figure 1-5).100,101 
Replication Stress Response 
Lesions resulting from replication stress are perhaps the greatest threats facing 
cells. If left unresolved, the consequences of incomplete genome duplication can result in 
mitotic catastrophe, chromosomal rearrangements, and cell death.74 Therefore, cells 
developed the replication stress response to ensure genome integrity in the face of these 
devastating lesions.  
Like other forms of DNA damage, replication stress can result from both 
endogenous and exogenous sources. Exogenous forms of replication stress include 
chemical mutagens like hydroxyurea and camptothecin, which cause replication fork 
stalling and double strand breaks respectively. In fact, any source of DNA damage that 
causes a lesion that is left unrepaired presents a barrier to replication fork progression and 
therefore is considered to be a source of replication stress. Endogenous replication stress 
often occurs at sites in the genome that are particularly difficult to replicate, such as areas  
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Figure 1-5. Homologous Recombination Repair.* General schematic depicting homologous 
recombination repair. DNA damage induces a double strand break, which is processed by nucleases to yield 
resected 3’ ends. This is followed by strand invasion and DNA synthesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev 
Biochem. 2008;77:229-257. doi:10.1146/annurev. biochem.77.061306.125255. 
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containing unusual DNA structures, common fragile sites, telomeres and other repetitive 
regions.102 Uncoupling of the DNA replication machinery is common at these 
aforementioned sites, resulting in slowing or stalling of the replication fork.103,104 This 
leads to the induction of a replication stress response to either facilitate replication restart 
or fork collapse, depending on the extent of damage.  
Replication stress can be resolved in various ways. Stalled replication forks 
typically have extensive RPA—ssDNA, which acts as a platform for the activation of the 
ATR pathway described above. ATR signaling results in the activation of many 
downstream effectors that promote fork stability.99 After these initial stages, the cell will 
either promote replication restart or fork collapse. If the damage is severe, replication 
fork collapse is induced either by conversion of single strand breaks (SSB) to double 
strand breaks (DSB) during replication or through direct action of endonuclease 
cleavage.105,106 DSBs resulting from collapsed replication forks can be repaired by 
homologous recombination, which was described in detail above. Briefly, DNA resection 
is followed by strand invasion and assembly of a new replication fork.107 If the damage is 
not as severe, replication fork restart is promoted. Restart of stalled replication forks 
depends on the concerted effort of several DNA helicases and translocases. Recently, 
SMARCAL1 was identified as one of the most abundant proteins bound to persistently 
stalled or collapsed replication forks.108,109 
SMARCAL1 
SMARCAL1 (SWI/ SNF-related, matrix-associated, actin-dependent regulator of 
chromatin, subfamily A-like 1), also known as the HepA-related protein (HARP), is a 
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member of the SNF2 family of helicases. Most SNF2 proteins are chromatin remodelers 
that utilize ATP hydrolysis to facilitate replication, recombination, and DNA repair. 
Although SMARCAL1 is implicated in these functions and uses ATP hydrolysis, it has 
an enzymatic activity unique to its SNF2 family members. SMARCAL1 is an ATP-
dependent helicase that reanneals ssDNA.110  
SMARCAL1 is composed of three critical domains: an RPA binding domain 
(RBD), two adjacent HARP domains (2HP), and a conserved SNF2 helicase domain. The 
RBD resides in the N-terminal region of SMARCAL1. Several groups have demonstrated 
that the RBD is essential to localize SMARCAL1 to stalled replication forks.111–113 
Sequence analysis of the SMARCAL1 gene identified a conserved RPA binding in the N-
terminal region, which is present in many DNA repair factos.111 RPA is a protein that 
binds to and stabilizes ssDNA during replication and DNA repair activities. Given 
SMARCAL1’s putative RBD and its affinity for forked DNA structures, many 
hypothesized that SMARCAL1 associated with RPA, which is commonly found at the 
transitions between ssDNA and dsDNA. It was demonstrated by immunoaffinity 
chromatography and co-immunoprecipitations that SMARCAL1 and RPA interact 
directly.111–113 Furthermore, it was determined that the first 30 amino acids at the N-
terminal region are critical for this interaction to occur. However, the RBD is not required 
for SMARCAL1’s helicase activity in vitro.111–114 The 2HP domain is essential for 
annealing helicase activity.114 Even when the 2HP domain is fused to other SNF2 domain 
containing proteins, like BRG1 or HELLS, it confers annealing helicase activity as 
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opposed to the traditional unwinding helicase activity of these SNF2 family members.114 
The conserved SNF2 domain, in the c-terminal region, confers the ATPase activity.110 
SMARCAL1 was first identified in the context of SIOD (Schimke 
immunoosseous dysplasia), an autosomal recessive disorder characterized by pleiotropic 
developmental deficiencies. Mutations in SMARCAL1 are both sufficient and necessary 
to cause SIOD.115 However, the mechanistic basis of this disease was unknown, in part 
because the cellular significance of SMARCAL1 was unknown. SMARCAL1 has since 
been identified as a replication stress response protein.111–113 
Given the role of RPA in the replication stress response, it was hypothesized that 
perhaps SMARCAL1 was recruited by RPA to sites of damage. In fact, several groups 
demonstrated that SMARCAL1 is recruited to multiple forms of DNA damage, including 
hydroxyurea induced fork stalling, Camptothecin produced DSBs, and laser-induced 
damage.111–113 Additionally, this recruitment was shown to be dependent on the 
interaction between SMARCAL1 and RPA. Further studies illustrated that SMARCAL1 
loss resulted in persistent loading of phosphorylated RPA onto chromatin, a marker of 
damage, and eventually fork collapse.112,116 SMARCAL1 promotes replication fork 
restart by catalyzing DNA annealing, branch migration, fork regression, and fork 
restoration, cementing it as a mediator of the replication stress response.110,117,118  
Overexpression and silencing of SMARCAL1 results in replication associated 
damage.112 Specifically, unregulated SMARCAL1 leads to replication fork collapse 
mediated by the endonuclease complex SLX4/MUS81, emphasizing the importance of 
proper enzymatic regulation.116,119 A known regulator of the replication stress response, 
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ATR also regulates SMARCAL1 activity.112,120 Through a feedback mechanism, ATR 
phosphorylates SMARCAL1 on Serine 652, inhibiting its activity and preventing 
aberrant fork processing.116 These examples demonstrate that both too much and too little 
SMARCAL1 activity can be detrimental to the cell, thus highlighting the idea that many 
proteins must work in concert to ensure appropriate responses to stress and damage.  
DDR proteins and telomere maintenance 
Given the role of homologous recombination in the ALT pathway, it is not 
surprising that many of the DNA damage response factors from the HR pathway are also 
involved in ALT. Examples relevant to the work in this thesis are described below.  
MRN Complex 
Components of the MRN complex were the first to be identified as required for ALT-
mediated telomere maintenance.46,48 As stated above, MRN senses DNA damage and 
promotes the recruitment of ATM. When MRN is inhibited, ALT cells undergo telomere 
shortening.46,48,121 
SLX4 endonuclease 
SLX4 is part of an endonuclease complex that is responsible for resolving HR 
intermediates. SLX4 is known to directly interact with TRF2, which is hypothesized to 
facilitate SLX4 function at telomeres.47,62,122,123 Additionally, SLX4 is responsible for 
recruiting several other nuclease complexes to telomeres. Depletion of SLX4 in ALT 
results in a decrease in telomere sister chromatid exchange events. It is hypothesized that 
SLX4 negatively regulates telomere elongation in ALT by resolving HR intermediates in 
the absence of telomere synthesis. 
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Mus81 endonuclease 
Mus81 is hypothesized to play a role in telomere maintenance but not telomere 
elongation in ALT.124 Mus81 is part of an endonuclease complex recruited by SLX4, and 
like SLX4, depletion of Mus81 also results in decreased telomere sister chromatid 
exchange events.124 Mus81 is known to play a role in recombinational repair of stalled or 
broken replication forks normally, and it is hypothesized that Mus81 also plays a role in 
the repair of stalled replication forks in ALT cells.105,125,126 
ATR 
Provided that ATR is a critical regulator of HR, many have hypothesized that 
ATR plays a significant role in the ALT pathway. Studies demonstrating the suppression 
of ATR by the shelterin component POT1 further underscored the potential importance of 
ATR regulation at telomeres. The highly recombinogenic state of ALT telomeres coupled 
with the association of RPA at single stranded regions of the telomere promotes the 
recruitment and activity of ATR. Therefore, ALT telomeres are primed for unregulated 
ATR activity. In fact, we demonstrate that ALT cells rely on ATR for telomere 
maintenance, highlighting it as a significant regulator of the ALT pathway.   
RAD51 
RAD51 is a recombinase that plays a central role in the process of HR, which 
highlights it as a potentially important factor in the ALT pathway. RAD51 assembles 
nucleoprotein filaments at DNA breaks to begin the search for a homologous target 
sequence. It is hypothesized that ALT cells may favor a switch at single stranded 
telomeric DNA from POT1 to RAD51. This would effectively alter the protective state of 
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telomeres to a recombinogenic state, which may facilitate the initiation of the ALT 
process. A recent study has further emphasized the role of RAD51 in ALT. Cho and 
colleagues demonstrated that RAD51 was essential to promote telomere clustering in 
ALT cells.44 Telomere clustering is one potential mechanism ALT cells utilize to 
promote telomere elongation. Essentially, DSBs initiate a RAD51 dependent homology 
search that recruits telomeres to PML bodies to engage in HR dependent telomere 
synthesis. The role of RAD51 in HR and telomere clustering highlight it as an important 
factor in the ALT pathway.   
Section Four: Concluding Remarks 
Telomere maintenance mechanisms are attractive therapeutic targets due to their 
absence in normal cells. Telomerase inhibitors are currently in the clinical trial phase of 
testing, but there are no therapeutics targeting the ALT pathway. Unlike telomerase, the 
ALT pathway is not very well characterized. This gap in knowledge has greatly hindered 
efforts in identifying viable therapies for ALT positive cancers, highlighting the need to 
dissect the molecular mechanisms regulating ALT activity. Given the fragility of ALT 
telomeres, we hypothesized that the regulation of replication stress is a requisite for 
maintenance of the ALT pathway. We support this hypothesis through completion of the 
following two aims.  
 
AIM ONE. Determine whether the ATR kinase plays a key role in regulating the 
ALT pathway. The ATR kinase is a critical regulator of the cellular response to 
replication stress. We hypothesize that the telomeres of ALT cells are prone to replication 
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stress, and therefore require ATR for survival. We highlight the abundance of replication 
stress at ALT telomeres by targeting ATR to induce cell death, effectively inhibiting the 
ability of ALT cells to manage the stress at their telomeres. 
 
AIM TWO. Determine whether SMARCAL1 functions in the ALT pathway. 
SMARCAL1 is a replication stress response protein that promotes the restart of stalled 
replication forks. The incorporation of variant repeats at ALT telomeres may disrupt 
shelterin binding, which results in frequent fork stalling. Therefore, we hypothesize that 
SMARCAL1 bolsters replication at ALT telomeres, which are a particularly fragile 
region. We demonstrate the importance of managing replication stress in ALT by 
identifying SMARCAL1 as a novel telomere maintenance protein and a critical regulator 
of ALT activity.  
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CHAPTER TWO: MATERIALS AND METHODS 
 Section One: Chapter three materials and methods 
Cell culture 
U2OS, SAOS2, HeLa, SW26, and SW39 cells were cultured in DMEM, 10% FBS, 1% 
LGlutamine, and 1% Penicillin/Streptomycin. MG63, SKLU1, CALU6, and NY cells 
were grown in DMEM F12, 5% FBS, 1% Penicillin/Streptomycin. SJSA1, NOS1, 
HUO9, and G292 cells were grown in RPMI 1640, 5% FBS, 1% Sodium Pyruvate, 1% 
Penicillin/Streptomycin. CAL78 was grown in RPMI 1640, 10% FBS, 1% Sodium 
Pyruvate, 1% Penicillin/Streptomycin. CAL72 was grown in DMEM F12, 10% FBS, and 
1% Penicillin/Streptomycin. BJ fibroblasts were grown in EMEM, 10% FBS, 1% 
penicillin/Streptomycin. MGG119 and MGG4 were grown in neurobasal medium 
(Invitrogen) supplemented with L-glutamine (3 mM; Mediatech), B27 supplement 
(Invitrogen), N2 supplement (Invitrogen), heparin (5 mg/ml; Sigma), EGF (20 ng/ml; R 
and D systems), and FGF2 (20 ng/ml; Peprotec). MG63, SAOS2, SJSA1, NOS1, HUO9, 
NY, G292 and CAL78 were obtained from the Center for Molecular Therapeutics at 
Massachusetts General Hospital. SW26 and SW39 were a kind gift of W. Wright (UT 
Southwestern). BJ fibroblasts were obtained from ATCC. 
siRNAs, probes and antibodies 
Stealth siRNA targeting ATRX #1 (UUCCAUAGCCGUCUCAAGAUUCUCA) and #2 
(UAUAGAAUUCUGAUCAUCA) was obtained from Invitrogen. ATRX knockdown 
was analyzed by Western blot 72 hr after transfection using RNAi MAX. siRNA for ATR 
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(CCUCCGUGAUGUUGCUUGA) and ATM (GCCUCCAGGCAGAAAAAGAtt) were 
obtained from Invitrogen and experiments were preformed 72 hr after transfection using 
RNAi MAX. 
The following antibodies and probes were used where indicated, ATR (Bethyl), ATM 
(Bethyl), ATRX (Santa Cruz), rabbit TRF2 (Bethyl), mouse TRF2 (Millipore), PML 
(Santa Cruz), RPA32 (Thermo Scientific), RAD52 (Santa Cruz), γH2AX (Millipore), and 
αTubulin (Cell Signaling), PNA-TAMRA-(CCCTAA) (Custom Biosynthesis), PNA-
FITC-(TTAGGG) (Custom Biosynthesis), 28S (AACGATCAGAGTTTTCACC). 
Cell synchronization and FACS 
Cells were treated with 2 mM thymidine, 0.1 mg/ml nocodazole, or 7 μM RO3306, for 
16-18 hr. Thymidine released cells were either washed three times in PBS, once in 
growth media, and then collected at the indicated time points or washed and released into 
7 μM RO3306 for 20 hr. For FACS, cells were collected by trypsin, washed with PBS, 
and resuspended in PBS containing 1 mM EDTA. Cells were fixed by addition of ice-
cold ethanol overnight. Fixed cells were washed in PBS, and stained with PBS, 0.1 mM 
EDTA, 1% BSA, 0.25% Tween 20, 10 μg/ml propidium iodide, 0.5 mg/ml RNaseA, for 
20 min at 37°C. Samples were analyzed using a FACSCalibur cytometer. 
Immunofluorescence analysis 
Cells were extracted with 0.25% Triton, fixed in 3% paraformaldehyde, and further 
permeablized with 0.5% Triton. Cells were subsequently incubated with the primary 
antibodies (diluted in PBS containing 3% BSA and 0.05% Tween 20) overnight at 4°C in 
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a humidified chamber. Following extensive washing with PBS, cells were incubated with 
secondary antibodies for 45 min at room temperature, and washed again with PBS. After 
a 5 min incubation with DAPI, cells were mounted on slides with Vectashield. Slides 
were analyzed using a Nikon H600L fluorescence microscope or Zeiss LSM 710 
confocal microscope. For HeLa cells with ATRX knockdown, 1 x 105 cells were reverse 
transfected with ATRX siRNA using Lipofectamine RNAi Max (Invitrogen), seeded onto 
coverslips, and incubated for 48 hr. After 48 hr, cells were treated with 2 mM thymidine 
for 16 hr, washed and released, and processed at the indicated time points. For ATR or 
ATM knockdown in U2OS cells, 0.75x 105 cells were reverse transfected with ATR or 
ATM siRNA using Lipofectamine RNAi Max (Invitrogen), seeded onto coverslips, and 
incubated for 72 hr before APB analysis. To enhance the percentage of cells positive for 
APB, U2OS cells were seeded at 1.5 x 105 and allowed to incubate overnight. The 
following day methionine free media was added to the cells and they were incubated for 
an additional 84 hr.  
RNA FISH 
HeLa or U2OS cells adhered to coverslips were incubated for 7 min on ice, in ice-cold 
freshly made CSK buffer (100 mM NaCl, 300 mM Sucrose, 3 mM MgCl2, 10 mM 
PIPES pH 7, 0.5% Triton X-100, 10 mM Vanadyl Ribonucleoside Complex). Cells were 
then rinsed in 1x PBS and fixed in 4 % Paraformaldehyde for 10 min at room 
temperature. The coverslips were rinsed in 70% ethanol and dehydrated in a series of 
ethanol washes (70%, 85%, 100%) for 5 min each at room temperature. After drying the 
coverslips at 37°C, they were then incubated with 10 nM PNA-TAMRA-(CCCTAA) 
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probe in hybridization buffer (50% formamide, 2x SSC, 2 mg/ml BSA, 10% dextran 
sulfate, 10mM Vanadyl Ribonucleoside complex) for 16 hr at 37°C. Coverslips were 
washed in 2x SSC + 50% formamide 3 times at 39oC for 5 min, 3 times in 2xSSC at 
39°C for 5 min each, and finally 1 time in 2x SSC + 100 ng/ml DAPI at room 
temperature for 10 min. Coverslips were mounted on glass microscope slides using 
VectaShield and sealed with nail polish. 
Combined Immunofluorescence FISH 
For Combined Immunofluorescence DNA FISH, cells were rinsed with PBS and treated 
with cytobuffer (100 mM NaCl, 300 mM sucrose, 3mM MgCl2, 10 mM PIPES pH 7, 
0.1% Triton-X 100) for 7 min at 4°C. Cells were then rinsed with PBS and fixed in 4% 
paraformaldehyde for 10 min at room temperature. Cells were then permeabilized in 
0.5% NP40/PBS for 10 min and blocked in PBG (0.5% BSA, 0.2% fish gelatin, PBS) for 
1 hr at room temperature. Cells were then incubated with the indicated antibodies diluted 
in PBG and incubated overnight at 4°C. Following incubation with primary antibody, the 
cells were washed three times with PBST (PBS containing 0.1% Triton) for 10 min each 
and subsequently incubated with secondary antibody diluted in PBG for 45 min at room 
temperature. The cells were washed three times with PBST for 10 min each and then 
fixed in 4% paraformaldehyde for 10 min at room temperature. Fixation was followed by 
digestion with RNaseA 200 mg/ml in 2x SSC for 30 min at 37°C. Cells were then 
dehydrated in a series of ethanol washes 70%, 85%, 100% for 2 min each at room 
temperature, and the coverslips were dried at 37°C for 20 min. 10 nM PNA-TAMRA-
(CCCTAA) probe in hybridization buffer (50% formamide, 2x SSC, 2mg/ml BSA, 10% 
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dextran sulfate) was added to coverslips and DNA was denatured at 75°c for 3 min and 
then place in humidified chamber at 39°C overnight. The following day, the coverslips 
were washed in 2x SSC +50% formamide three times at 39°C for 5 min each, three times 
in 2xSSC at 39°C for 5 min each, and finally one time in 2x SSC at room temperature for 
10 min. The coverslips were mounted on glass microscope slides with Vectashield 
mounting medium containing DAPI and analyzed using a Nikon H600L fluorescence 
microscope. 
Combined Immunofluorescence RNA FISH experiments were performed exactly as 
above except for the following modifications. The initial incubations in cytobuffer 
included 10 mM Vanadyl Ribonucleoside Complex. The RNaseA digestion step was 
omitted prior to dehydration. The denaturation step was omitted during probe 
hybridization. 
Telomere sister chromatid exchange assay 
Cells were incubated with a 3:1 ratio of bromodeoxyuridine to bromodeoxycytidine 
(BrdU/BrdC, 10 mM/3.3 mM) for 16 h before nocodazole was added and the cells were 
incubated for an additional 45 min. Cells were collected by trypsinization, incubated in 
75mM KCL at 37°C for 20 min, and then fixed in ice cold 3:1 methanol/acetic acid. Cells 
were then centrifuged, supernatant aspirated, and resuspended in fresh fixative. This was 
repeated twice before fixed cells were dropped onto glass slides. Slides were treated with 
0.5 mg/ml 1 RNaseA in 2x SSC at 37°C for 10 min, incubated in 2x SSC containing 10 
mg/ml Hoescht 33258 for 15 min, and then exposed to 365-nm UV light (Stratalinker 
1800) for 30 min. Slides were then incubated in 10 U/ml ExoIII for 10 min at 37°C to 
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degrade nicked DNA. Slides were dehydrated in an ethanol series [70% (v/v), 85% (v/v) 
and 100% ethanol] and allowed to air dry overnight. Slides were then incubated with a 
fluorescein isothiocyanate (FITC)-labeled G-rich telomeric peptide–nucleic acid (PNA) 
probe PNA-FITC-(GGGAT) in hybridization buffer (50% formamide, 2x SSC, 2 mg/ml 
BSA, 10% dextran sulfate) for 1 hr at room temperature and then washed in PBS 
containing 0.02% (v/v) Tween-20 for 10 min at room temperature. Subsequently, slides 
were incubated in PNA-TAMRA-(CCCTAA) probe for 1 hr at room temperature and 
washed in PBS containing 0.02% (v/v) Tween-20 for 20 min at 57°C. Finally, slides were 
incubated with 1 mg/ml DAPI in 2xSSC containing 0.02% (v/v) Tween-20 for 5 min and 
sealed with coverslips. Telomere sister-chromatid exchange events were imaged using a 
Zeiss LSM710 Confocal microscope and analyzed using Fiji software. 
C-circle assay 
C-circle assays were performed as previously described2. Briefly, genomic DNA was 
purified using the Qiagen DNA Blood Mini Kit according the manufacturer’s 
instructions. Purified DNA, was digested with AluI and MboI restriction enzymes at 
37°C overnight. The digested DNA was again purified over a Qiagen PCR clean-up 
column and the DNA was quantified using a Nanodrop spectrophotometer. The DNA (40 
ng) was diluted in 10 μl 1× Φ29 Buffer (NEB) containing BSA (NEB; 0.2 mg/ml), 0.1% 
Tween, 0.2 mM each dATP, dGTP, dTTP, and incubated in the presence or absence of 
7.5 U ΦDNA polymerase (NEB) at 30°C for 8 hr, followed by 65°C for 20 min. C-circle 
amplification products were detected by dot blot using a DIG-labeled probe (CCCTAA)4. 
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Live-cell imaging 
HeLa and RPE-1 cells stably expressing H2B-mRFP, and U2OS cells stably expressing 
both H2B-mRFP and 53BP1-GFP, were grown on glass-bottom 12-well tissue culture 
dishes (Mattek) in phenol red-free DMEM:F12 medium (10% FBS, 100 IU/ml penicillin, 
and 100 mg/ml streptomycin). Cells were treated with 5 μM VE or an equivalent volume 
of DMSO and imaged on a Nikon Ti-E inverted microscope enclosed within a 
temperature and CO2- controlled environmental chamber that maintained an atmosphere 
of 37°C and 5% humidified CO2. Fluorescent images were captured every 15 min for 36 
hr with a 20X (0.75 NA) objective and 2 X 2 binning to minimize light exposure. At least 
4 separate fields of view were acquired for each condition. Images were subsequently 
analyzed using NIS-Elements software. Cells were scored as having undergone a 
“normal” mitosis if no micronuclei were generated following the first anaphase; “slightly 
abnormal” if 1-3 micronuclei were generated; or “highly abnormal” if 4 or more 
micronuclei were generated. Only the first mitosis following drug addition was scored. 
Quantitative Reverse Transcriptase PCR 
HeLa cells were reverse transfected using Lipofectamine RNAiMax and incubated for 48 
hr. Following this incubation, either 2 mM thymidine or 0.1 mg/ml nocodazole was 
added to cells and incubated for an additional 18 hr. The cells were collected and RNA 
was extracted using the RNeasy Mini kit. Following quantification, 1 mg of total RNA 
was reverse transcribed using the oTEL primer and SuperScript III Reverse Transcriptase 
for 1 hr at 55°C, followed by a 70°C incubation for 15 min. cDNA was amplified using 
the SYBR green master mix with the indicated primers and analyzed using the Roche 
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Light Cycler 480 with the following PCR conditions, 95°C 10 min, (98°C 15 sec, 60°C 
20 sec, 72°C 1 min) x 39, 72°C 5 min. Primer sequences for oTEL, 15q, and Xp/Yp are 
as follows:  
oTEL 5’ (CCCTAA)5 3’  
15q Forward 5’-CAGCGAGATTCTCCCAAGCTAAG-3’ 
15q Reverse 5’-AACCCTAACCACATGAGCAACG-3’ 
Xp/Yp Forward 5’ GCAAAGAGTGAAAGAACGAAGCTT-3’ 
Xp/Yp Reverse 5’-CCCTCTGAAAGTGGACCAATCA-3’ 
Telomere-repeat amplification protocol 
TRAP assays were performed using the TRAPeze telomerase detection kit (Millipore) 
according to the manufacturer’s recommendations. For TRAP assay on HeLa cells, HeLa 
cells were reverse transfected with siRNA against ATRX using Lipofectamine RNAiMax 
and incubated for 72 hr.  HeLa, osteosarcoma, and glioblastoma cell lines were collected 
by trypsinization and counted to obtain 1 x 106 cells. Cells were resuspended 1x CHAPS 
Lysis buffer and incubated on ice for 30 min. Lysates were centrifuged at 12,000x g for 
20 min at 4oC and protein concentration was determined using Bradford reagent. 
Approximately, 150 ng of total protein was used in each reaction and PCR amplification 
reactions were performed as recommended. DNA products were separated by 10% PAGE 
in 0.5x TBE run at 200 V for 2 hr and visualized using SYBR gold. 
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Cellular viability 
For cell viability assays, between 250-1,500 cells were seeded per well, in triplicate, of a 
96- well plate and incubated overnight. The following day cells were either left untreated, 
or treated with increasing concentrations of VE-821, KU-55933, AZ20, or Gemcitabine. 
The cells were incubated for 4-6 days and cell viability was analyzed using CellTiter Glo 
and a SpectraMax M5 plate reader. IC50s were calculated using Excel or Prism software. 
For analysis of cell death, cells were seeded in a 6-well dish at 0.5 x 105 and allowed to 
incubate for 8 hr. Cells were either left untreated, or treated with 3 mM VE-821 and 
incubated for 6 days. Cells were collected by trypsin and stained for FACS analysis using 
the Annexin V assay kit (Life Technologies) per the manufacturer’s recommendations. 
Cell death was analyzed using FACS Diva Software. 
For analysis of population doubling, U2OS cells were seeded at 0.6 x 105 and RPE were 
seeded 0.3 x 105 every 3-4 days in growth media with, or without, 1.5mM VE821. Cells 
were collected by trypsinization and counted using a hemacytometer for a total of 21 
days. Population doubling was calculated using the standard formula PD= 
log(Nfinal/Ninitial)/log(2). 
DNA-protein binding assay using biotinylated ssDNA 
Biotinylated ssTEL [(TTAGGG)8] was attached to streptavidin-coated magnetic beads in 
10 mM Tris-HCl (pH 8.0), 100 mM NaCl at room temperature for 30 min. The 
biotinylated ssTEL (0.4 pmol) was first incubated with purified RPA (1.2 pmol) for 30 
min at room temperature. Recombinant RPA complex was purified from E. coli as 
previously described1. The RPA precoated ssTEL was retrieved with a magnet and 
  
35 
subsequently mixed with increasing concentrations of whole cell extracts (WCE) for 30 
min at room temperature. The RPA coated ssTEL was again retrieved using a magnet and 
the amount of RPA still bound to the ssTEL was analyzed by Western blot with the 
indicated antibody. To generate WCE, cells were lysed in binding buffer [10mM Tris-
HCl (pH 7.5), 600 mM NaCl, 10 mg/ml BSA, 10% glycerol, 0.05% NP-40] and sonicated 
for 10 sec at a power of 3, 3 times. Cell lysates were normalized with a binding buffer 
containing no salt and then added to the RPA-coated ssTEL reactions. For binding assays 
on HeLa cells, HeLa cells were either mock treated or reverse transfected with siRNA 
against ATRX (Lipofectamine RNAiMax) and incubated for 48 hr. Cells were then left 
untreated or incubated with 2 mM thymidine or 0.1 mg/ml nocodazole for 16-18 hr and 
then collected with trypsin prior to lysis.  
Dot blot 
RNA was purified using the RNAeasy purification kit and 2-10 μg was denatured in 50% 
formamide, 2.5 mM EDTA for 15 min at 65oC. The denatured RNA was loaded onto 
Hybond XL membrane using a BioRad dot blot vacuum manifold. The membrane was 
crosslinked for 35 sec at 125 J and washed briefly in 2x SSC. The membrane was then 
incubated in Ultra-Hyb hybridization buffer (Ambion) for 1 hr at 50oC. Telomeric 
(CCCTAA)4 or 28S (AACGATCAGAGTTTTCACC) probes were labeled using the 
DIG oligonucleotide 3’-End labeling Kit, 2nd Generation (Roche), according to the 
manufacturer’s instructions. DIG-labeled probe (10 pmole) was added to the Ultra-Hyb 
hybridization buffer and incubated with the membrane overnight at 50oC. The following 
day, the membrane was washed twice with 2x SSC + 0.1% SDS at room temperature for 
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5 min each and twice with 0.5x SSC + 0.1% DS at 55 oC for 15 min. The membrane was 
then developed using the DIG CDP-STAR detection system (Roche) according to the 
manufacturer’s instructions. When necessary, membranes were stripped by boiling in 
0.1% SDS for 15 min at room temperature and reprobed. Fold change in TERRA was 
calculated after normalization to 28S using ImageLab software.  
Statistics 
Unpaired t-tests were used to determine the significance of data sets. ‘N’ represents 
biological replicates.  
Section Two: Chapter four materials and methods 
Cell culture 
SaOS2 cells were grown in McCoy’s 5A, 15% FBS, 1% penicillin/Streptomycin. HeLa 
and HeLa 1.2.11 cells were cultured in DMEM, 10% FBS, 1% LGlutamine, and 1% 
Penicillin/Streptomycin. RPE and Cal72 cells were grown in DMEM F12, 10% FBS, 1% 
Penicillin/Streptomycin. SJSA1 and HuO9 cells were grown in RPMI 1640, 5% FBS, 1% 
Sodium Pyruvate, 1% Penicillin/Streptomycin.  
siRNAs, probes and antibodies 
All siRNA transfections were performed using Invitrogen RNAi MAX according to 
manufacturer’s instructions.  Stealth siRNA targeting SMARCAL1 
(UUGCUAAGAAGGUCAAAGC) and the 3’UTR of SMARCAL1 
(UUUCACAGAGAAAUGCUUAUGCAGG) were obtained from Invitrogen. 
SMARCAL1 knockdown was analyzed by Western blot 72 hr after transfection. siRNA 
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for RAD51 (UGAUUAGUGAUUACCACUGct) was obtained from Ambion.  
Knockdown was analyzed by western blot 72 hours after transfection.  SLX4 
(GCUACCCGGACACUUGUCAUUGUUA), and Mus81 
(CAGCCCUGGUGGAUCGAUAtt) were obtained from Invitrogen and experiments 
were preformed 72 hr after transfection. TRF1 siRNA #7 
(CAGUAGUAGUCCUUUGAUATT) and TRF1 siRNA #6 
(ACGUAUUCUGUAAAGCUUATT) were obtained from Qiagen.  TRF1 knockdown 
was analyzed by western blot of nuclear extracts 48 hours after transfection. 
The following antibodies and probes were used where indicated, SMARCAL1 (Santa 
Cruz), PML (Santa Cruz), RPA32 (Thermo Scientific), pRPA S4S8 (Bethyl), Mus81 
(abcam), SLX4 (Bethyl), RAD51 (Santa Cruz), γH2AX (Millipore), TRF1 (Millipore), 
and αTubulin (Cell Signaling), PNA-TAMRA-(CCCTAA) (Custom Biosynthesis), PNA-
FITC-(TTAGGG) (Custom Biosynthesis). 
Plasmids 
Flag-SMARCAL1 plasmid was obtained as a generous gift from Alexandre Marechal. 
The MYC-TRF2 plasmid was obtained from Addgene (16066).  Both plasmids were 
transfected using Fugene transfection reagent (Promega) according to the manufacturer’s 
instructions.   
Combined Immunofluorescence FISH 
For Combined Immunofluorescence DNA FISH, cells were rinsed with PBS and treated 
with cytobuffer (100 mM NaCl, 300 mM sucrose, 3mM MgCl2, 10 mM PIPES pH 7, 
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0.1% Triton-X 100) for 7 min at 4°C. Cells were then rinsed with PBS and fixed in 4% 
paraformaldehyde for 10 min at room temperature. Cells were then permeabilized in 
0.5% NP40/PBS for 10 min and blocked in PBG (0.5% BSA, 0.2% fish gelatin, PBS) for 
1 hr at room temperature. Cells were then incubated with the indicated antibodies diluted 
in PBG and incubated overnight at 4°C. Following incubation with primary antibody, the 
cells were washed three times with PBS for 5 min each and subsequently incubated with 
secondary antibody diluted in PBG for 45 min at room temperature. The cells were 
washed three times with PBS for 5 min each and then fixed in 4% paraformaldehyde for 
10 min at room temperature. Fixation was followed by digestion with RNaseA 200 
mg/ml in 2x SSC for 30 min at 37°C. Cells were then dehydrated in a series of ethanol 
washes 70%, 85%, 100% for 2 min each at room temperature, and the coverslips were 
dried at 37°C for 20 min. 10 nM PNA-TAMRA-(CCCTAA) probe in hybridization 
buffer (50% formamide, 2x SSC, 2mg/ml BSA, 10% dextran sulfate) was added to 
coverslips and DNA was denatured at 75°c for 3 min and then place in humidified 
chamber at 39°C overnight. The following day, the coverslips were washed in 2x SSC 
+50% formamide three times at 39°C for 5 min each, three times in 2xSSC at 39°C for 5 
min each, and finally one time in 2x SSC at room temperature for 10 min. The coverslips 
were mounted on glass microscope slides with Vectashield mounting medium containing 
DAPI and analyzed using a Zeiss LSM-710 confocal microscope.  
Telomeric Chromatin Immunoprecipitation Assay 
SaOS2 and HeLa cells were fixed with 1% formaldehyde for 10 minutes at room 
temperature.  Fixation was quenched with .125M Glycine.  Cells were subsequently 
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scraped and pelleted in ice cold PBS.  Pellets were then lysed with cellular lysis buffer (5 
mM PIPES, 85 mM KCl, 0.5% NP40) on ice for 10 minutes.  Nuclear pellets were 
isolated by centrifugation at 850 rpm at 4◦C, and were then lysed in nuclear lysis buffer 
(50 mM Tris pH 8, 10 mM EDTA pH 8, 0.2% SDS) and sonicated at 4◦C.  Sonicated 
chromatin was then spun down at 13000xg for 10 minutes.  The chromatin was then 
quantified using a Nanodrop spectrophotometer and incubated with 2µg of the indicated 
antibodies overnight at 4◦C.  Chromatin-antibody conjugates were then 
immunoprecipitated at 4◦C for 1.5 hours. Immunoprecipitates were extensively washed 
with Dilution IP buffer (16.7 mM Tris pH 8, 1.2 mM EDTA, 167 mM NaCl, 0.1% SDS, 
1.1% Triton-X 100) twice, TSE (20 mM Tris pH 8, 2mM EDTA pH 8, 500mM NaCl, 1% 
Trition X-100, and 0.1% SDS) once, LiCl buffer (100mM Tris pH 8, 500 mM LiCl, 1% 
deoxycholic acid, and 1% NP40) once, and TE (10mM Tris pH 8 and 1mM EDTA pH 8).  
The beads were eluted in 50mM NaHCO3, 140mM NaCl and 1% SDS at 55◦C for 1 hour 
and the samples were subsequently decrosslinked overnight at 65◦C.  Immunoprecipitates 
were detected by dot blot using a DIG-labeled probe (CCCTAA)4. 
Terminal Restriction Fragment Analysis by Southern Blot 
Breifly, genomic DNA was purified using the Qiagen DNA Blood Mini Kit according to 
the manufacturer’s instructions.  Purified DNA was then digested with AluI and MboI 
restriction enzymes at 37◦C overnight.  Digested DNA was then electrophoresed on 0.7% 
agarose gels at 30V for 1 hour and then 70V overnight in 0.5X TBE buffer.  After 
electrophoresis, the gels were transferred overnight to a Hybond XL membrane by 
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Southern blot, and telomeric restriction fragments were detected using a DIG-labeled 
probe (CCCTAA)4.  
C-circle assay 
Genomic DNA was purified using the Qiagen DNA Blood Mini Kit according the 
manufacturer’s instructions. Purified DNA, was digested with AluI and MboI restriction 
enzymes at 37°C overnight. The digested DNA was again purified over a Qiagen PCR 
clean-up column and the DNA was quantified using a Nanodrop spectrophotometer. The 
DNA (40 ng) was diluted in 10 μl 1× Φ29 Buffer (NEB) containing BSA (NEB; 0.2 
mg/ml), 0.1% Tween, 0.2 mM each dATP, dGTP, dTTP, and incubated in the presence or 
absence of 7.5 U ΦDNA polymerase (NEB) at 30°C for 8 hr, followed by 65°C for 20 
min. C-circle amplification products were detected by dot blot using a DIG-labeled probe 
(CCCTAA)4. 
Dot blot 
C-circle amplification products were loaded onto Hybond XL membrane using a BioRad 
dot blot vacuum manifold. The membrane was crosslinked for 35 sec at 125 J and washed 
briefly in 2x SSC. The membrane was then incubated in Ultra- Hyb hybridization buffer 
(Ambion) for 1 hr at 50oC. A telomeric (CCCTAA)4 probe was labeled using the DIG 
oligonucleotide 3’-End labeling Kit, 2nd Generation (Roche), according to the 
manufacturer’s instructions. DIG labeled probe (10 pmole) was added to the Ultra-Hyb 
hybridization buffer and incubated with the membrane overnight at 50oC. The following 
day, the membrane was washed twice with 2x SSC + 0.1% SDS at room temperature for 
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5 min each and twice with 0.5x SSC + 0.1% SDS at 50 oC for 15 min. The membrane 
was then developed using the DIG CDP-STAR detection system (Roche) according to the 
manufacturer’s instructions.  
Metaphase Spreads 
Cells were incubated in nocodazole for 2hrs, collected by trypsinization, and then 
incubated in 75mM KCl at 37 for 20 minutes.  Cells were fixed in ice cold fixative (3:1 
Methanol/acetic acid) before dropping on glass slides.  Slides were incubated with 
Geimsa for 20 minutes and analyzed with a Nikon Eclipse Ti at 63x. 
Fractionation of cell extracts  
SaOS2 cells were lysed in buffer A (10 mM HEPES pH7.9, 10 mM KCl, 1.5 mM MgCl2, 
0.34 M Sucrose, 10% glycerol, 0.1% Triton X-100, 1 mM DTT, and protease inhibitors).  
The isolated nuclei were subsequently lysed with buffer B (3 mM EDTA, 0.2 mM 
EGTA, 1 mM DTT, and protease inhibitors). Nuclear pellets were extracted with buffer C 
(10 mM HEPES pH7.9, 100 mM NaCl, 2mM MgCl2, 0.5% NP-40, and protease 
inhibitors).  The pellets were sonicated at 100% amplitude for three 30 second pulses, 
then the pellets were incubated overnight at 4◦C. The soluble nuclear proteins in buffer B 
and the proteins extracted from nuclear pellets with buffer C were combined, and the 
final concentration of NaCl was adjusted to 300 mM.  The resulting extracts were 
combined with 2x SDS sample buffer and analyzed by Western blot. 
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Flow cytometric analysis of cell cycle 
SaOS2 cells were either mock treated or treated with SMARCAL1 siRNA for 72 hours 
and then were collected and fixed in ice-cold 70% ethanol overnight at -20 °C. Cells were 
stained in PI staining buffer (PBS/ 0.1mM EDTA/ 1% BSA/ 0.25% Tween/ RNAseA/ 
10µg/ml Propidium Iodide). All samples were analyzed by flow cytometry on a BD 
FACSCalibur and data was subsequently analyzed by FlowJo software.  
Statistics 
Unpaired t-tests were used to determine the significance of data sets. ‘N’ represents 
biological replicates.  
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CHAPTER THREE: ALTERNATIVE LENGTHENING OF TELOMERES 
RENDERS CANCER CELLS HYPERSENSITIVE TO ATR INHIBITORS 
Section One: Abstract 
Cancer cells rely on telomerase or the alternative lengthening of telomeres (ALT) 
pathway to overcome replicative mortality. ALT is mediated by recombination and 
prevalent in a subset of human cancers, yet whether it can be exploited therapeutically 
remains unknown. Loss of ATRX associates with ALT in cancers. Here, we show that 
ATRX loss compromises the cell-cycle regulation of the telomeric non-coding RNA 
TERRA and leads to persistent association of RPA with telomeres after DNA replication, 
creating a recombinogenic nucleoprotein structure. Inhibition of ATR, a critical regulator 
of recombination recruited by RPA, disrupts ALT and triggers chromosome 
fragmentation and apoptosis in ALT cells. Importantly, the cell death induced by ATR 
inhibitors is highly selective for ALT cells across a panel of cancer cell lines, suggesting 
that ATR inhibition is a potential therapeutic strategy in the treatment of ALT-positive 
cancers.  
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Section Two: Introduction 
Cancer cells overcome replicative senescence by activating telomerase or the 
alternative lengthening of telomeres (ALT) pathway.9,29,127 ALT is used in ~5% of all 
human cancers and is prevalent in specific cancer types, including osteosarcoma and 
glioblastoma.128 Currently, there are no therapies specifically targeting ALT. ALT relies 
on recombination to elongate telomeres, but how the recombinogenic state of ALT 
telomeres is established remains elusive.29 In contrast to the cancer cells defective for 
homologous recombination (HR) and susceptible to PARP inhibition, 129,130 ALT-positive 
cells are HR-proficient.131 Thus, the reliance of ALT on recombination raises an 
important question as to whether recombination can be exploited in ALT-positive cancers 
as a means for targeted therapy.  
Section Three: Results and Discussion 
Loss of ATRX compromises cell cycle regulation of TERRA 
Single-stranded DNA (ssDNA) coated by replication protein A (RPA) is a key 
intermediate in both DNA replication and HR.85 RPA transiently associates with 
telomeres during DNA replication, but is released from telomeres after S phase.61,132 The 
release of RPA may be an important mechanism to suppress HR at telomeres. The 
association of RPA with telomeres in S phase is facilitated by TERRA, the telomere 
repeat-containing RNA, which is also present at telomeres during this period.58,59,61,133 To 
understand how ALT is established, we asked if the association of TERRA with 
telomeres is altered in ALT cells. TERRA colocalized with the telomere-binding protein 
TRF2 in telomerase-positive HeLa cells (Fig. S1).61 However, in both HeLa and   
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Figure 3-1. Loss of ATRX compromises the cell-cycle regulation of TERRA. (A) RNA fluorescence in 
situ hybridization (FISH) analyses of TERRA in HeLa, SJSA1, U2OS, and HUO9 cells during the cell 
cycle. TERRA foci colocalized with TRF2 at telomeres (figs. S1 and S3, A and B). To enrich cells in S 
phase, cells were treated with thymidine alone. To enrich cells in G2, cells were first arrested in S phase 
with thymidine and then released into medium containing the CDK1 inhibitor RO3306 (fig. S2). Scale bar: 
10 μm. (B) The percentage of cells positive for TERRA foci (>5 foci) was graphed as the mean ± SD (n = 
2). (C) HeLa cells were mock treated or treated with ATRX siRNA, and RNA FISH analysis of TERRA 
was performed after thymidine release. The knockdown of ATRX was confirmed by Western blot (fig. 
S5A). Cells were enriched in late S and G2 phases 7 hours after thymidine release (fig. S5B). Scale bar: 10 
μm. (D) The percentage of cells positive for TERRA foci was graphed as the mean ± SD (n = 3). (E and F) 
HeLa cells were mock treated or treated with ATRX siRNA, and were enriched in S or M phase with 
thymidine and nocodazole, respectively (fig. S5B). TERRA was analyzed by reverse transcription 
quantitative polymerase chain reaction (RT-qPCR) using the subtelomeric primers of chromosome 15q or 
Xp/Yp. The results are graphed as the mean fold change ± SD (15q n = 3, Xp/Yp n = 4). *P < 0.05. 
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telomerase-positive SJSA1 cells (see Fig. S24B), the levels of TERRA foci declined from 
S phase to G2 (Fig. 3-1A-B, S2). 61,133 Although in ALT-positive U2OS cells TERRA 
also colocalized with the telomere marker TRF2 (Fig. S3A-B), neither the levels of 
TERRA, nor the colocalization of TERRA and TRF2, declined from S to G2 (Fig. S2, 
S3B-C, S4A-B). Furthermore, in ALT-positive U2OS and HUO9 cells (see Fig. 3-3D, 
S25A-B), the levels of TERRA foci elevated significantly in S phase and remained high 
into G2 (Fig. 3-1A-B, S2). Thus, unlike in telomerase-positive cells, ALT cells are 
defective in the cell-cycle regulation of TERRA. 
 We next asked why TERRA persistently associates with telomeres in ALT cells. 
Recent studies have revealed a correlation of ALT with loss of ATRX in cancer.50–52,134 
ATRX was detected in HeLa but not U2OS (Fig. S5A, see Fig. S25C),50 prompting us to 
test if the dysregulation of TERRA in ALT cells is a result of ATRX loss. Indeed, 
knockdown of ATRX in HeLa cells resulted in persistent TERRA foci, and elevated 
TERRA levels in G2/M (Fig. 3-1, C and D, S5, S6). Furthermore, the levels of TERRA 
derived from individual telomeres (15q and Xp/Yp) declined from S phase to mitosis in 
control HeLa cells but not in ATRX knockdown cells (Fig. 3-1, E and F). These results 
suggest that TERRA is repressed by ATRX in G2/M.  
Loss of ATRX compromises RPA release from telomeres 
Considering that RPA is released from telomeres in G2/M when TERRA is 
repressed by ATRX,61 we asked if ATRX is required for the release of RPA. In HeLa 
cells, numerous small replication-associated RPA foci (type-A RPA foci) were detected 
in S phase (Fig. S7). As cells progressed from S to G2, type-A RPA foci became largely  
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 Fig. 3-2. Loss of ATRX compromises RPA release from telomeres. (A) HeLa cells were mock treated 
or treated with ATRX siRNA, and RPA and TRF2 foci were analyzed in S and G2phases as in Fig. 1C. 
Scale bar: 10 μm. (B) The percentage of cells positive for RPA foci was graphed as the mean ± SD (n = 2) 
*P = 0.008 (left) and *P = 0.002 (right). (C) HeLa cells were either mock treated or treated with ATRX 
siRNA, and whole-cell extracts (WCE) were generated from cells in S or M phase. Biotinylated ssTEL was 
coated with RPA and incubated with the WCE. After the incubation, ssTEL was retrieved, and the 
remaining RPA32 on ssTEL was analyzed by Western blot. (D) SW39TEL and SW26ALT cells were 
analyzed for ATRX protein expression by Western blot. (E) SW39TEL and SW26ALT cells were analyzed for 
TERRA transcript by dot blot with digoxigenin-labeled anti-TERRA or 28S RNA probes. (F) 
Quantification of dot blots for TERRA transcript in SW39TEL and SW26ALT cells. TERRA signal was 
normalized to 28S signal, and ratios were graphed as the mean ± SD (n = 2). *P = 0.001. (G) RPA-ssTEL 
was incubated in WCE from SW39TEL or SW26ALTcells. The RPA32 remaining on ssTEL was analyzed by 
Western blot.  
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undetectable (Fig. 3-2A). However, upon ATRX knockdown, bright damage-associated 
RPA foci (type-B RPA foci) were detected at telomeres in a fraction of G2 cells (Fig. 3-
2A, S7, S8). Knockdown of ATRX with two independent siRNAs led to a significant 
increase of type-B RPA foci in G2 cells (Fig. 3-2B). To examine the release of RPA from 
telomeric ssDNA biochemically, we followed this process in cell extracts using an in 
vitro assay that we previously established.61 A biotinylated ssDNA oligo of telomeric 
repeats (ssTEL) was coated with recombinant RPA and incubated in extracts from S-
phase or mitotic HeLa cells. Consistent with the release of RPA from telomeres in G2/M, 
RPA was released from ssTEL more efficiently in mitotic extracts than in S-phase 
extracts (Fig. 3-2C).61 Knockdown of ATRX reduced the release of RPA from ssTEL in 
mitotic extracts (Fig. 3-2C), demonstrating that ATRX contributes to the RPA release in 
G2/M. To test if the loss of ATRX in ALT cells affects RPA release, we analyzed 
IMR90-derived SW39TEL (telomerase-positive) and SW26ALT (ALT-positive) cells (Fig. 
S9).131 ATRX was detected in SW39TEL but not SW26ALT (Fig. 3-2D). Moreover, the loss 
of ATRX in SW26ALT associated with a 4-fold increase of TERRA compared with 
SW39TEL (Fig. 3-2E-F). Importantly, RPA was released from ssTEL more efficiently in 
SW39TEL cell extracts than in SW26ALT cell extracts (Fig. 3-2G), showing that ALT cells 
lacking ATRX indeed have a reduced ability to release RPA from telomeric ssDNA. 
Given that RPA-ssDNA is a key HR intermediate, we asked if ATRX loss induces 
ALT. Knockdown of ATRX in HeLa cells did not inactivate telomerase, nor did it induce 
telomere lengthening (Fig. S10A-B). These results are consistent with a previous study50 
and suggest that loss of ATRX is insufficient to establish ALT. Nevertheless, ATRX 
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knockdown in HeLa cells promoted some features of ALT, such as the persistent 
association of TERRA and RPA with telomeres. Interestingly, a recent study showed that 
loss of ASF1 led to the acquisition of several ALT phenotypes, including accumulation of 
RPA at telomeres.135 We postulate that ALT is established via a multistep process in 
which loss of ATRX poises telomeres for ALT, but additional genetic/epigenetic changes 
are needed to fully activate the ALT pathway (see Fig. S29). 
ATR inhibitor disrupts ALT activity 
RPA-ssDNA is not only an HR intermediate, but also the nucleoprotein structure 
that recruits the key HR regulator ATR kinase.86,136 The defective RPA release from 
telomeres in ATRX knockdown cells and ALT cells suggests that ATR may be recruited 
to telomeres during the establishment of ALT. Consistent with our hypothesis, ATR 
colocalizes with PML in U2OS cells but not in HeLa cells,137 suggesting its presence in 
APBs (ALT-associated PML bodies).38 Furthermore, ATRIP, the regulatory partner of 
ATR, associates with telomeres in ALT-positive WI38-VA13 cells but not in HeLa 
cells.138 These findings prompted us to test if ATR is functionally required for ALT. The 
ATR inhibitor VE-821139 and ATR siRNA significantly reduced APBs in U2OS and 
SW26ALT cells (Fig. 3-3, A and B, S11A-B, S12A). VE-821 also disrupted APBs in 
U2OS cells synchronized in G2 (Fig. S12B)121, ruling out cell-cycle changes as the cause 
of APB dispersal. In marked contrast, the ATM inhibitor KU-55933 and ATM siRNA did 
not affect APBs in U2OS cells (Fig. 3-3, A and B, S12B-C), highlighting the role for 
ATR, but not ATM, in the maintenance of APBs in ALT cells.   
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Fig. 3-3. ATR inhibitor disrupts ALT activity (Part I). (A) U2OS cells were mock treated, treated with 5 
μM VE-821 or 5 μM KU-55933, or treated with siRNA for ATR or ATM, and then immunostained for 
TRF2 and PML. The percentage of cells positive for APBs was graphed as the mean ± SD; experiment was 
performed in triplicate (n = 3).P < 0.02. (B) Representative images from cells quantified in (A). Scale bar: 
10 μm. (C) U2OS cells were mock treated or treated with 2.5 μM VE-821 for 4 days and analyzed for T-
SCE events with G-rich (green) and C-rich (red) PNA probes. The fraction of chromosome ends with T-
SCE was quantified and graphed as the mean ± SD (Mock n = 1032, VE-821 n =1556). *P < 0.01.  
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Fig. 3-3. ATR inhibitor disrupts ALT activity (Part II). (D and E) HUO9 and U2OS cells were mock 
treated or treated with 5 μM VE-821 for 24 and 48 hours, respectively. C-circle amplification products 
were detected by dot blot in (D). The levels of C-circles were graphed in (E) as the mean ± SD (n = 2). 
Telomerase-positive SJSA1 cells were used as a negative control. P < 0.02. (a period is missed). (F) The 
fraction of chromosome ends with telomere loss was quantified and graphed as the mean ± SD (Mock n = 
1032, VE-821 n = 1556). *P < 0.01. 
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To determine the effects of VE-821 on the recombinogenic state of ALT 
telomeres, we analyzed telomere sister-chromatid exchange (T-SCE) and 
extrachromosomal telomeric C-rich DNA (C-circles) in ALT cells. VE-821 not only 
decreased T-SCE in U2OS cells (Fig. 3-3C, S13A), but also reduced C-circle levels in 
U2OS and HUO9 cells (Fig. 3-3, D and E), showing that ALT is indeed inhibited. 
Furthermore, VE-821 elevated the frequency of telomere loss in U2OS cells (Fig. 3-3F, 
S13B), suggesting that the stability of ALT telomeres is compromised. Consistent with 
the idea that TERRA acts upstream of ATR to promote RPA retention at ALT telomeres, 
VE-821 did not affect TERRA levels and telomere association in U2OS cells (Fig. S14A-
B).  
Selective killing of ALT cells by ATR inhibitor 
Incited by the effects of VE-821 on ALT telomeres, we asked if VE-821 
selectively kills ALT cells. SW26ALT was indeed more sensitive to VE-821 than SW39TEL 
(Fig. S15). Importantly, SW26ALT and SW39TEL were similarly sensitive to a panel of 
DNA-damaging agents (Fig. S16), demonstrating that the effects of VE-821 are unique to 
ATR inhibition but not a result of general genotoxicity. Moreover, VE-821 induced 
γH2AX more efficiently in SW26ALT than in SW39TEL (Fig. S17), suggesting that it 
inflicts more DNA damage in ALT cells. At a concentration that virtually eliminates 
U2OS cells, VE-821 only modestly reduced the proliferation of untransformed RPE-1 
cells (Fig. S18). Using H2B-mRFP and live-cell imaging, we followed the chromosome 
segregation in U2OS, HeLa, and RPE-1 cells after VE-821 treatment. Furthermore, we 
used 53BP1-GFP to visualize DNA double-stranded breaks (DSBs) in U2OS cells. VE-
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821 induced dramatic errors in anaphase chromosome segregation in U2OS but not HeLa 
or RPE-1 cells (Fig. 3-4, A and B, S19; Movie S1). In the following interphase, U2OS 
cells displayed increased micronucleation compared to HeLa or RPE-1 cells (Fig. S20A; 
Movie S1). Moreover, U2OS cells exhibited numerous 53BP1 foci (Fig. 3-4, A and C; 
Movie S1). A fraction of the 53BP1 foci in U2OS cells colocalized with telomeres (Fig. 
3-4C, S20B). The colocalization of 53BP1 with telomeres but not centromeres was 
significantly induced by VE-821 (Fig. S21A-B), suggesting that ALT telomeres are 
particularly fragile upon ATR inhibition. Interestingly, knockdown of ATRX in HeLa 
and BJ cells did not increase the induction of γH2AX by VE-821 or VE-821 sensitivity 
(Fig. S22A-C), suggesting that while ATRX loss may prime cells for ALT, it is not 
directly responsible for the vulnerability of ALT cells to ATR inhibition. 
Given the prevalence of ALT in osteosarcoma,140 we tested the effects of VE-821 
on a panel of osteosarcoma cell lines. These cell lines clearly clustered into two groups 
(Fig. 3-4D). The mean IC50 of VE-821 for one group (U2OS, SAOS2, CAL72, NOS1, 
and HUO9) was ~0.8 μM, whereas the mean IC50 for the other group (MG63 and 
SJSA1) was ~9 μM (Fig. 3-4D, S23A). Among these lines, U2OS and SAOS2 are known 
ALT lines without detectable ATRX protein (Fig. S24A).50 CAL72, NOS1, and HUO9 
lacked detectable telomerase activity, ATRX protein, and displayed APBs (Fig. S24A-C, 
S25A-C), suggesting that they are also ALT-positive. In contrast, MG63 and SJSA1 were 
positive for telomerase activity, ATRX protein, and negative for APBs (Fig. S24A-C). In 
this panel of cell lines, VE-821 induced substantially higher levels of apoptosis in the 
ALT lines than in the telomerase-positive lines (Fig. 3-4E). The hypersensitivity of ALT 
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cells to ATR inhibition was confirmed with a second ATR inhibitor (Fig. S23B). In 
contrast to ATR inhibitors, neither the ATM inhibitor KU-55933 nor the DNA replication 
inhibitor gemcitabine showed significant selectivity toward ALT cells (Fig. 3-4D, S23C-
D). Notably, several ATRX-expressing ALT lines were also hypersensitive to VE-821 
(Fig. S25A-D, S26A-B),50 again suggesting that the state of ALT telomeres but not 
ATRX loss per se renders cells hypersensitive to ATR inhibitors.  
ALT is prevalent not only in osteosarcoma but also in pediatric glioblastoma.122  
MGG119, a newly developed glioma stem cell (GSC) line,141 lacked detectable 
telomerase activity and ATRX protein, but expressed high levels of TERRA and 
displayed APBs (Fig. S27A-D), suggesting that it is ALT-positive. In contrast, the GSC 
line MGG4 was positive for telomerase activity and ATRX protein, but expressed low 
levels of TERRA and lacked APBs (Fig. S27A-D).142 Importantly, although MGG119ALT 
and MGG4TEL were similarly sensitive to a panel of DNA-damaging agents (Fig. S28A-
C), MGG119ALT was significantly more sensitive to VE-821 than MGG4TEL (Fig. 3-4F), 
suggesting that VE-821 is uniquely effective in killing ALT GSCs. 
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Fig. 3-4. Selective killing of ALT cells by ATR inhibitor (Part I). (A and B) Stills from time-lapse live-
cell imaging experiments of (A) U2OS cells stably expressing H2B-mRFP and 53BP1-GFP or (B) HeLa 
cells expressing H2B-mRFP after treatment with either 5 μM VE-821 or vehicle control (dimethyl 
sulfoxide, DMSO). Colored arrows mark individual cells as they progress through mitosis. Time scale: 
hours:minutes. Scale bar: 30 μm. At least 150 cells were scored for each condition over two independent 
experiments. (C) U2OS cells were treated with VE-821 as in (A) and analyzed by immunofluorescence 
with 53BP1 and TRF2 antibodies. Scale bar: 10 μm.  
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 Fig. 3-4. Selective killing of ALT cells by ATR inhibitor (Part II). (D) A panel of osteosarcoma cell 
lines were mock treated, treated with VE-821, or treated with KU-55933 for 4 to 6 days. Cell viability was 
determined with CellTiter Glo. Dots represent IC50 concentrations calculated from experiments performed 
in triplicate (n = 3). (E) The osteosarcoma cell lines were treated with 3 μM VE-821 for 6 days, and cell 
death was quantified by annexin V staining. Induced cell death is shown as the mean ± SD (n = 2). (E) 
MGG4TEL and MGG119ALT cells were treated with increasing concentrations of VE-821 for 6 days. Cell 
viability was determined with CellTiter Glo. Error bars represent SDs; experiment was performed in 
duplicate (n = 2). 
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Section Four: Concluding Remarks 
The HR defects of specific cancers have offered an opportunity for targeted 
therapy using PARP inhibitors.129,130 However, in contrast to HR-defective cancers, ALT-
positive cancers actively use recombination to sustain immortality. We show that ATR 
inhibitors disrupt ALT (Fig. S29) and selectively kill ALT cells in vitro, suggesting the 
first rational strategy for the treatment of ALT-positive cancers. Furthermore, we show 
that functional recombination, like HR defects, can be targeted in specific contexts, 
presenting proof of a new therapeutic principle. Several ATR inhibitors have been 
recently developed and begun to enter clinical trials.139,143–146 Our findings highlight that 
a subset of cancers reliant on recombination are hypersensitive to ATR inhibitors, 
offering an unexplored direction for future preclinical and clinical studies.  
 
.
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CHAPTER FOUR: SMARCAL1 RESOLVES REPLICATION STRESS AT ALT 
TELOMERES 
Section One: Abstract 
Cancer cells overcome replicative senescence by exploiting mechanisms of 
telomere elongation, a process often accomplished by reactivation of the enzyme 
telomerase. However, a subset of cancer cells lack telomerase activity and rely on the 
alternative lengthening of telomeres (ALT) pathway, a recombination-based mechanism 
of telomere elongation. Although the mechanisms regulating ALT are not fully defined, 
chronic replication stress at telomeres might prime these fragile regions for 
recombination. Here, we demonstrate that the replication stress response protein 
SMARCAL1 is a critical regulator of ALT activity. SMARCAL1 associates with ALT 
telomeres to resolve replication stress and ensure telomere stability. In the absence of 
SMARCAL1, persistently stalled replication forks at ALT telomeres deteriorate into 
DNA double-strand breaks promoting the formation of chromosome fusions. Our studies 
not only define a role for SMARCAL1 in ALT telomere maintenance, but also 
demonstrate that resolution of replication stress is a crucial step in the ALT mechanism. 
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Section Two: Introduction 
Telomeres cap the ends of chromosomes and function as a barrier shielding the 
human genome from nucleolytic degradation and illegitimate recombination. Telomeres 
are composed of double-stranded TTAGGG hexameric repeats that are organized into a 
lariat, or T-loop, at the end of each chromosome.8 While this structure is essential to 
prevent chromosome ends from being recognized as DNA double strand breaks (DSBs), 
T-loops pose a natural impediment to DNA replication.17–21 In addition, the G-rich 
sequence drives Hoogsteen base-pairing between guanosine nucleotides generating G-
quadruplex structures that pose a threat to the processivity of the replication 
machinery.22,23 The repetitive nature and structural complexities of the telomeric DNA 
induce frequent replication fork stalling and chromosome breakage demonstrating that 
telomeres are common fragile sites within the genome.24–26 Therefore, understanding how 
cells have evolved to navigate the replication stress associated with telomeric DNA is 
essential to our understanding of genome stability. 
Common fragile sites are associated with an increased rate of recombination 
suggesting that telomere fragility promotes recombination at telomere ends.103,147 The 
link between telomere fragility and recombination is most evident in cancer cells that rely 
on the alternative lengthening of telomeres (ALT) pathway. The ALT pathway promotes 
telomere elongation using homology directed recombination between telomeric DNA 
sequences.63,64,148 Although in cancer cells telomere elongation is often achieved by 
reactivation of the enzyme telomerase, subsets of cancer cells activate the ALT pathway 
for telomere maintenance.33 The exact mechanisms driving activation and maintenance of 
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the ALT pathway are not fully defined, however, telomere deprotection and changes in 
chromatin dynamics may represent early events in the ALT process. In ALT cells, the 
telomere sequence has evolved such that in addition to the canonical TTAGGG sequence 
these telomeres have an increase in variant hexameric repeats including TCAGGG, 
TTCGGG, and GTAGGG.69,70 Variant repeats drive telomere deprotection by disrupting 
binding of the telomere repeat factors TRF1 and TRF2; components of the telomere 
capping complex, Shelterin. Loss of TRF1 increases replication fork stalling and 
enhances telomere fragility.25,26 This fragility is exacerbated by defects in nucleosome 
assembly at telomeres as genetic mutations in the chromatin remodeling complex a-
thalassemia/mental retardation syndrome X-linked/deathdomain-associated protein 
(ATRX/DAXX) and histone variant H3.3 are highly correlated with ALT positive 
cancers.52,134 In addition, loss of the histone chaperone ASF1 (anti-silencing factor 1) in 
mammalian cells, which promotes histone transfer during replication, leads to the 
induction of ALT-like phenotypes.135 Therefore, limited telomere end protection and 
altered chromatin dynamics stress an already fragile repetitive region during replication, 
enhancing replication stress and consequently promoting telomere instability. Together, 
these events may prime telomeres for recombination and as a result promote ALT 
activity. 
 The telomeric DNA in ALT cells is incredibly dynamic constantly undergoing 
rapid attrition and elongation providing one of the first indications that telomeres in ALT 
cells rely on recombination to promote telomere elongation.148 This was later supported 
by studies demonstrating that the telomeres in ALT cells are recruited into nuclear foci 
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that, in addition to the promyelocytic leukemia (PML) protein, contain a number of 
recombination and repair factors including RPA, RAD51, RAD52, BRCA1, MRE11, 
RAD50, and NBS1.38,40,41,149 The formation of the ALT-associated PML bodies (or APB) 
led to early speculations that APB functioned as platforms for recombination. More 
recently, it was demonstrated that inhibition of replication, or the sensing of replication 
stress, could disrupt APB formation.49,135 These findings raise the possibility that as 
common fragile sites, replication fork stalling at the telomere drives APB formation to 
either promote fork restart or salvage collapsed forks through recombination. Given the 
repetitive nature of telomeres, recombination can occur between nonhomologous 
chromosomes, sister chromatids, or extrachromosomal telomeric repeat (ECTR) DNA. 
ECTR DNA can exist in both linear and circular forms composed of double stranded or 
partially single-stranded, C-rich or G-rich telomeric sequences.35,36 Partially single-
stranded C-rich circular ECTR, or C-circles are unique to ALT cells and have been 
demonstrated to directly correlate with ALT activity.150,151 ECTR are likely generated as 
a byproduct of recombination, however, they may also perpetuate the ALT phenotype by 
functioning as a template for recombination.33 Similar to the formation of APB, C-circle 
formation is significantly reduced following inhibition of replication, or the sensing of 
replication stress.49,135 Taken together, these cellular phenotypes highlight the 
contribution of replication stress to telomere recombination, and ultimately, provocation 
of the ALT pathway. 
 Given the fragility of telomeric DNA, understanding how the telomere responds 
to replication stress will undoubtedly further our understanding of both telomere 
  
64 
maintenance and the progression toward cancer. Recently, the annealing helicase 
SMARCAL1 was identified as one of the most abundant proteins bound to persistently 
stalled, or collapsed, replication forks.108,109 SMARCAL1 (SWI/ SNF-related, matrix-
associated, actin-dependent regulator of chromatin, subfamily A-like 1), also known as 
the HepA-related protein (HARP), is an ATP-dependent DNA annealing helicase that 
remodels chromatin surrounding stalled replication forks to promote replication 
restart.110,112,117,152 Therefore, we speculated that SMARCAL1 might function to remodel 
stalled replication forks at telomeric DNA and bolster replication through a particularly 
fragile region. Here, we demonstrate that SMARCAL1 is enriched at telomeric DNA in 
cells that rely on the ALT pathway for telomere maintenance indicating that ALT 
telomeres are prone to chronic replication stress. In the absence of SMARCAL1, 
persistently stalled replication forks at ALT telomeres form DNA double-strand breaks, 
induce RAD51-dependent telomere clustering, promote chromosomal fusions, and drive 
genome instability. Our studies demonstrate a function for SMARCAL1 in the resolution 
of replication stress at telomeric DNA and also define SMARCAL1 as a critical regulator 
of the ALT pathway. Defining the molecular mechanisms regulating maintenance of the 
ALT pathway is critical to both our understanding of telomere biology and also the 
progression toward cancer. 
Section Three: Results and Discussion 
SMARCAL1 is significantly enriched at ALT telomeres 
SMARCAL1 was identified as a chromatin remodeling enzyme that functions to 
restart stalled replication forks by catalyzing branch migration and fork 
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regression.112,117,152 Given the prevalence of replication stress at telomeres, we asked 
whether SMARCAL1 functioned to alleviate replication stress and promote telomere 
maintenance. To do this, we initially asked whether SMARCAL1 associated with 
telomeric DNA in unperturbed mammalian cells. Using a combined immunofluorescence 
and in situ hybridization (IF-FISH) approach, we detected SMARCAL1 protein at 
telomeres in ALT positive SaOS2ALT and HuO9ALT cells (Figures 4-1A and 4-1B), 
however, we did not detect SMARCAL1 at telomeres in telomerase-positive HeLaTEL or 
untransformed RPEUNT cells (Figures 4-1A, 4-1B, and S1 A). The association of 
SMARCAL1 with telomeres in ALT positive cells was robust with 60% of cells 
demonstrating at least one SMARCAL1-telomere colocalization event (Figure 4-1B). 
Remarkably, this association of SMARCAL1 with telomeres was restricted exclusively to 
APB as we were unable to detect SMARCAL1 at telomeres that had not been recruited to 
PML bodies (Figures 4-1C and 4-1D). The association of SMARCAL1 with ALT 
telomeres was not simply attributed to highly repetitive regions as we could not detect 
SMARCAL1 at centromeric DNA by IF-FISH (Figure S1 B). To further validate the 
specificity of SMARCAL1 binding at telomeric DNA, we performed chromatin 
immunoprecipitation assays. Similar to the results from our IF-FISH experiments, 
SMARCAL1 was significantly enriched at the telomeric DNA in SaOS2ALT cells but 
not in HeLaTEL cells (Figures 4-1E and 4-1F). Moreover, the binding of SMARCAL1 at 
ALT telomeres was significantly enriched over SMARCAL1 binding to the Alu repeats 
further highlighting the specificity of SMARCAL1 binding at ALT telomeres (Figures S1 
C and S1 D). 
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Figure 4-1. SMARCAL1 Accumulates at ALT Telomeres (Part I). (A) Combined immunofluorescence 
and DNA fluorescence in situ hybridization (IF-FISH) analyses of SMARCAL1 and telomeres in SaOS2, 
HuO9, and HeLa cells. Representative images are shown. Scale bar, 10 µm. (B) The percentage of cells 
positive for 0, 1–2, 3–4, 5–6, and 7 or greater incidences of SMARCAL1 colocalizing with telomeres in 
SaOS2, HuO9, and HeLa cells are graphed as the mean of three independent experiments (n = 3). Scale bar, 
10 µm. (C) IF-FISH analyses of SMARCAL1, PML, and telomeres in SaOS2 and HuO9 cells. Scale bar, 
10 µm. (D) Quantification of experiments performed in (C). Percentage of cells positive for APB and 
SMARCAL1 colocalizing with APB are graphed as the mean ± SD (n = 2). 
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Figure 4-1. SMARCAL1 Accumulates at ALT Telomeres (Part II). (E) ChIP for telomeric DNA 
associated with SMARCAL1 and TRF2 in SaOS2 and HeLa cells co-expressing FLAG-SMARCAL1 and 
MYCTRF2. (F) Quantification of dot blots performed in (E). Graph represents average percent of telomeric 
DNA recovered in two independent experiments ± SD. 
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To further understand the association of SMARCAL1 with ALT telomeres, we 
asked whether we could promote SMARCAL1 relocalization to non-ALT telomeres by 
inducing replication stress. To do this, we took advantage of a HeLaTEL cell line 
derivative that maintains long telomeres, HeLaTEL1.2.11 and consequently, is vulnerable 
to replication stress. In fact, even in undamaged HeLaTEL1.2.11 cells, we could detect 
rare instances of colocalization between SMARCAL1 and telomeric DNA by IF-FISH. 
To determine whether these infrequent colocalization events are truly representative of 
sites of replication stress, we asked whether we could increase the frequency of these 
events by inducing replication stress specifically at telomere ends. Considering the role of 
TRF1 in telomere replication, we asked whether loss of TRF1 would induce frequent fork 
stalling at telomeres and promote the accumulation of SMARCAL1 at telomeric DNA in 
HeLaTEL1.2.11 cells. Therefore, we depleted TRF1 from HeLaTEL1.2.11 cells and 
either left them untreated or exacerbated replication stress with aphidicolin and analyzed 
the association of SMARCAL1 with telomeric DNA by IF-FISH. In the absence of 
TRF1, cells treated with aphidicolin demonstrated an increase in the phosphorylated form 
of RPA pS4/S8 at telomere ends, and these foci colocalized with SMARCAL1 suggesting 
the formation of irreversibly stalled replication forks (Figures S1 E– S1 G).153–155 These 
results demonstrate that SMARCAL1 does in fact associate with non-ALT telomeres, but 
this association is highly dependent on replication stress.156 Moreover, the abundance of 
SMARCAL1 at telomeres in ALT cells in the absence of exogenous replication stress 
suggests that ALT telomeres undergo chronic replication stress highlighting an 
unexplored function for SMARCAL1 in maintenance of the ALT pathway. 
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Loss of SMARCAL1 promotes telomere clustering in ALT 
The association of SMARCAL1 with ALT telomeres led us to hypothesize that 
SMARCAL1 localizes to telomeres in ALT to resolve persistently stalled replication 
forks and promote telomere stability. Thus, we predicted that loss of SMARCAL1 in 
ALT would lead to defects in replication fork restart, promote the accumulation of 
collapsed replication forks, and consequently increase APB formation. Consistent with 
this reasoning, loss of SMARCAL1 led to a significant increase in the percentage of cells 
positive for APB (Figures 4-2A– 4-2C) highlighting the contribution of replication stress 
to APB formation. SMARCAL1 loss did not lead to changes in the distribution of cells 
throughout the cell cycle, ruling out the possibility that the accumulation of APB was a 
result of cell-cycle arrest (Figure S2 A). In addition to the increase in APB, we observed 
a 17-fold increase in mean telomere foci size in a subset of cells depleted for 
SMARCAL1, as compared to the mean telomere foci size in control cells (Figure S2 B). 
The percentage of cells with large telomere foci increased by 4-fold following 
SMARCAL1 depletion in the ALT positive cells SaOS2ALT, CAL72ALT, and 
HuO9ALT (Figures 4A and S2C). In contrast, these large telomeric foci were entirely 
absent in HeLaTEL cells further supporting a unique role for SMARCAL1 at ALT 
telomeres (Figure 4-2D). Furthermore, we also observed an increase in the large telomere 
foci size using an alternative small interfering RNA (siRNA) targeting the 3’ UTR of  
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Figure 4-2. SMARCAL1 Inhibits the Formation of Double-Stranded DNA Breaks at Telomeres (Part 
I). (A) SaOS2 cells were mock-treated or treated with SMARCAL1 siRNA for 72 hr, and PML and 
telomere foci were analyzed by IF-FISH. Scale bar, 10 µm. (B) The percentage of cells positive for APB 
(colocalization of PML and telomere) was graphed as the mean ± SD (n = 3). *p < 0.005. (C) Western blot 
of SMARCAL1 in SaOS2 cells either mock-treated or treated with SMARCAL1 siRNA for 72 hr. Tubulin 
is used as a loading control. (D) Representative images of DNA FISH analyses of telomere foci in HeLa, 
CAL72, HuO9, and SaOS2 cells either mock-treated or treated with SMARCAL1 siRNA for 72 hr. Scale 
bar, 10 µm. (E) Quantification of experiments performed in (D). Graph represents percentage of cells 
positive for telomere > 2 µm was graphed as the mean ± SD (n = 3 SaOS2, n = 2 HuO9, and CAL72). *p < 
0.0001 (SaOS2), *p < 0.05 (HuO9), *p < 0.001 (CAL72).  
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Figure 4-2. SMARCAL1 Inhibits the Formation of Double-Stranded DNA Breaks at Telomeres (Part 
II). (F) SaOS2 cells were mock-treated or treated with SMARCAL1 siRNA for 72 hr, and γH2AX and 
telomere foci were analyzed by IF-FISH. Scale bar, 10 µm. (G) Quantification of experiments performed in 
(F). Graph represents percentage of cells positive for colocalization of γH2AX and telomere foci was 
graphed as the mean ± SD (n = 3). *p < 0.005. (H) SaOS2 cells were either mock-treated, cotreated with 
Mus81 siRNA and SLX4 siRNA, treated with SMARCAL1 siRNA alone, or treated with SMARCAL1  
siRNA, Mus81 siRNA, and SLX4 siRNA for 72 hr. Telomere foci were analyzed by DNA FISH. Scale bar, 
10 µm. (I) Quantification of experiments performed in (H). Graph represents average percentage of cells 
positive for telomere foci > 2 µm± SD (n = 5 Mock, n = 2 siSLX4/siMus81, n = 5 siSM1, n = 5 siSM1/ 
siSLX4/siMus81). *p < 0.05. 
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SMARCAL1. Importantly, we could rescue the large telomere phenotype in these cells 
with exogenously expressed Flag-SMARCAL1 (Figures S2D and S2E). 
Large telomere foci size has been linked to the aggregation of telomeric DNA 
following the formation of DNA DSBs.44 Therefore, we considered the possibility that 
the larger telomeric foci following SMARCAL1 knockdown may reflect sites of 
persistent stalled replication forks that breakdown into DNA DSBs. The percentage of 
cells demonstrating the large telomere phenotype steadily accumulated over time, 
reaching a maximum of 60% cells containing larger telomeric foci after 5 days (Figures 
S2F and S2G). These large foci were specific to telomeric DNA as we did not observe an 
increase in centromeric DNA foci size in the absence of SMARCAL1 (Figure S2H). 
Finally, the large telomeric foci demonstrated a significant increase in colocalization with 
gH2AX reinforcing the speculation that these telomeres represent sites of DSBs (Figures 
4-2F and 4-2G). 
Stalled replication forks represent a roadblock to cellular proliferation. Therefore, 
persistently stalled forks are subject to cleavage by the SLX-MUS endonuclease 
complex.106,157,158 Once cleaved, these replication forks are repaired through homologous 
recombination.159,160 The SLX4 and MUS81 nuclease have been shown to localize to 
APB in ALT cells and regulate ALT activity.124,161 Therefore, we asked whether the 
SLX-MUS endonuclease complex was responsible for the generation of the large 
telomere foci formed in ALT cells following SMARCAL1 knockdown. In fact, in 
SMARCAL1-deficient ALT cells also containing siRNA for MUS81 and SLX4, we 
observed a significant decrease in the percentage of cells containing the large telomeric  
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Figure 4-3. Loss of SMARCAL1 Promotes RAD51-Dependent Telomere Clustering (Part I). (A) 
SaOS2 cells were either mock-treated or treated with SMARCAL1 siRNA for 72 hr, pRPA S4/S8 and 
telomere foci were analyzed by IF-FISH. Scale bar, 10 µm. (B) SaOS2 cells were either mock-treated or 
treated with SMARCAL1 siRNA for 72 hr, and RAD51 foci were analyzed by IF-FISH. Scale bar, 10 µm. 
(C) Quantification of experiments performed in (A) and (B). Graph represents the average percentage of 
cells positive for colocalization of RAD51 (left bar) and pRPA S4/S8 (right bar) with telomere foci > 2 µm. 
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Figure 4-3. Loss of SMARCAL1 Promotes RAD51-Dependent Telomere Clustering (Part II). (D) 
SaOS2 cells were either mock-treated, treated with SMARCAL1 siRNA alone, RAD51 siRNA alone, or 
co-treated with SMARCAL1 siRNA and RAD51 siRNA for 72 hr. Telomere foci were analyzed by DNA 
FISH. Scale bar, 10 µm. (E) Western blot of SMARCAL1 and RAD51 in SaOS2 cells either mock-treated, 
treated with SMARCAL1 siRNA alone, RAD51 siRNA alone, or co-treated with SMARCAL1 siRNA and 
RAD51 siRNA after 72 hr. Tubulin was used as a loading control. (F) Quantification of experiments 
performed in (D). Graph represents average percentage of cells with telomere foci > 2µm ± SD (n = 3). *p 
< 0.05. (G) SaOS2 cells were either mock-treated or treated with SMARCAL1 siRNA for 72 hr, and PML 
and telomere foci were analyzed by IF-FISH. Graph represents telomere foci > 2µm colocalized with zero, 
one, or two or greater PML foci. 
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foci (Figures 4-2H, 4-2I, S2I, and S2J). Previous studies have demonstrated that 
SMARCAL1 prevents the formation of MUS81-dependent DNA DSBs.117 Therefore, our 
data suggest that loss of SMARCAL1 in ALT cells leads to irreversibly stalled 
replication forks at telomeric DNA that are recognized and cleaved by the SLX-MUS 
endonuclease complex driving DSB formation. 
The generation of DSBs at ALT telomeres promotes RAD51- dependent 
telomeric clustering and consequently, primes telomeres for homology-directed repair.44 
Thus, we asked whether the DSBs at telomeric DNA in ALT cells following loss of 
SMARCAL1 also promote telomere clustering. In fact, following SMARCAL1 
knockdown, we observed a significant increase in the association of pRPA S4/ S8 with 
large telomere foci suggesting that these telomere ends contain irreversibly stalled 
replication forks that have collapsed into DSBs (Figures 4-3A and 4-3C).153–155 
Concomitant with RPA-coated telomeric DNA was the accumulation of the 
recombination protein RAD51 (Figures 4-3B and 4-3C). Notably, formation of the large 
telomere foci was dependent on RAD51 as SMARCAL1-deficient cells treated with 
RAD51 siRNA showed a significant reduction in large telomere foci (Figures 4-3D–F). 
These foci were largely devoid of 53BP1 although in some instances we could detect 
53BP1 on the periphery of the foci highlighting the increase in DNA DSBs and damage 
signaling at these telomere ends (Figure S3A). Similar to previous reports, these telomere 
clusters colocalized with PML, and a single large telomere often contained more than a 
single PML foci reinforcing the model that PML functions to promote telomere-telomere 
interactions (Figures 4-3 G and S3B).44,162 Taken together, our data suggest that loss of 
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SMARCAL1 induces DSBs at ALT telomeres and triggers RAD51-dependent telomere 
clustering. 
SMARCAL1 regulates ALT activity 
To further define the role of SMARCAL1 in ALT telomere maintenance, we 
asked whether DSBs and subsequent telomere clustering induced by SMARCAL1 loss 
would lead to significant changes in overall telomere heterogeneity. Therefore, we 
performed telomere restriction fragment (TRF) analysis on genomic DNA isolated from 
SMARCAL1-deficient cells. Loss of SMARCAL1 led to an increase in smaller telomeric 
DNA fragments that migrate below the bulk telomere signal as well as an increase in 
larger telomeric DNA fragments migrating above the bulk telomere signal (Figure 4-4A). 
These findings suggest that loss of SMARCAL1 leads to gross changes in telomere 
heterogeneity and supports a role for SMARCAL1 in maintaining ALT telomere stability. 
While the increase in smaller telomeric DNA fragments could be explained by the 
increase in DNA DSBs following SMARCAL1 knockdown, we speculated that the larger 
telomeric DNA fragments could represent unresolved recombination intermediates. 
The sheer abundance of telomeric DNA throughout the genome allows 
recombination during ALT to occur between homologous and/or nonhomologous 
chromosomes, chromosome fragments, and/or ECTR DNA. The C-rich circular ECTR 
DNA species, or C-circles, are unique to ALT-positive cells and have been shown to 
directly correlate with ALT activity. C-circles are thought to arise as byproducts of 
telomeric recombination and can be readily detected by Southern blot following rolling-
circle amplification. If the DSBs formed after loss of SMARCAL1 promote 
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recombination, we predicted that SMARCAL1 knockdown in ALT cells would lead to an 
increase in C-circle formation. As predicted, following SMARCAL1 knockdown, we 
demonstrate a 3-fold increase in C-circle abundance in ALT cells (Figures 4-4B and 4-
4C). However, in stark contrast, SMARCAL1 knockdown did not induce C-circle 
formation in HeLaTEL cells demonstrating that loss of SMARCAL1 can increase, but 
cannot induce, ALT activity (Figures S4A–S4C). To determine whether the increase in 
ALT activity and large telomere DNA fragments are indicative of unresolved 
recombination intermediates, we analyzed metaphase chromosome spreads from 
SMARCAL1-deficient SaOS2ALT and RPEUNT cells. Remarkably, in the absence of 
SMARCAL1 in SaOS2ALT cells we observed metaphase spreads containing chromatid-
type fusions (Figures 4-4D and 4-4E). However, these structural chromosome 
abnormalities were absent in RPEUNT cells following SMARCAL1 knockdown (Figures 
4-4D and 4-4E). Conceivably, in the absence of SMARCAL1, DNA DSBs formed by 
persistently stalled replication forks at ALT telomeres are forced to undergo 
recombination leading to an increase in ALT phenotypes. The increase in ALT telomeres 
primed for recombination overwhelms the repair machinery leading to defects in the 
resolution of recombination intermediates and emergence of structural chromosome 
abnormalities. 
  
  
78 
Figure 4-4. Loss of SMARCAL1 Increases ALT Activity and Induces Structural Chromosome 
Abnormalities (Part I). (A) SaOS2 cells were either mock-treated or treated with SMARCAL1 siRNA for 
12 days before isolation of genomic DNA. The isolated DNA was then digested and telomere restriction 
fragments were analyzed by Southern blot using telomere specific probes. (B) SaOS2 cells were either 
mock-treated or treated with SMARCAL1 siRNA for 72 hr. C-circle amplification products were loaded 
onto membranes by dot blot and analyzed by Southern blot using a telomere-specific probe. (C) The levels 
of C-circles were graphed as the mean ± SD (n = 3). *p < 0.05.  
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Figure 4-4. Loss of SMARCAL1 Increases ALT Activity and Induces Structural Chromosome 
Abnormalities (Part II). (D) Representative metaphase spread of mock treated (top) or SMARCAL1 
siRNA-treated (bottom) RPE (left) and SaOS2 (right) cells after 72 hr. Enlarged images represent incidence 
of chromatid- type fusions. Scale bar, 10 µm. (E) Quantification of experiments performed in (D). Graph 
represents percentage of metaphase spreads positive for fusion events containing > 3 chromosomes and was 
graphed as mean ± SD (n = 2, > 16 spreads per experiment). 
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Section Four: Concluding Remarks 
 Ultimately, we have demonstrated that the annealing helicase SMARCAL1 is a 
critical regulator of replication stress at telomeric DNA. The enrichment of SMARCAL1 
at telomeres in ALT cells demonstrates that ALT telomeres experience chronic 
replication stress and highlight SMARCAL1 as a critical regulator of the ALT pathway. 
SMARCAL1 associates with telomeric DNA in ALT cells and functions to mitigate 
replication stress and regulate ALT activity. Together, our data support a model in which 
SMARCAL1 binds ALT telomeres to resolve replication stress and facilitate telomere 
elongation. However, in the absence of SMARCAL1 stalled replication forks fail to 
restart and consequently, become substrates for cleavage by the SLX-MUS endonuclease 
complex. The formation of telomeric DNA DSBs drives telomere clustering and 
facilitates recombination to salvage collapsed replication forks and maintain telomere 
stability. Nevertheless, the accumulation of telomeric DNA DSBs following 
SMARCAL1 depletion saturates the capabilities of the repair machinery leading to the 
formation of unresolved recombination intermediates and genome instability. The 
enrichment of SMARCAL1 at ALT telomeres highlights both the prevalence of 
replication stress at ALT telomeres and also how resolution of this replication stress is 
critical for the maintenance of ALT activity. The ALT pathway is active in 10% of all 
cancers; thus, further defining the mechanisms regulating ALT activity could provide an 
opportunity for targeted therapeutic development. 
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CHAPTER FIVE: FINAL THOUGHTS & FUTURE DIRECTIONS 
 Although great strides have been made in defining the ALT mechanism, the 
factors and exact mechanisms that drive ALT activation remain elusive. The leading 
hypothesis posits that remodeling of the telomeric architecture contributes to the 
initiation and maintenance of ALT. Structural and compositional changes at the telomere 
can occur in many ways. One way is through telomere uncapping, which dramatically 
alters the telomere environment. The protective function of telomeres and shelterin 
provided to chromosome ends is termed ‘telomere capping.’ When telomeres undergo 
progressive shortening, they can be uncapped. This is thought to result from loss of 
sufficient shelterin binding and the inability to form the protective t-loop structure.163 The 
loss of shelterin leaves the telomere vulnerable to processing by many pathways, 
including ATM (ataxia telangiectasia mutated), ATR (ATM and Rad3-related), HR 
(homologous recombination), and NHEJ (non-homologous end joining).71 Aberrant 
activation of these pathways at chromosome ends leads to genomic instability. In normal 
cells, genomic instability and unregulated repair pathways often result in cell death. 
However, despite the high level of genetic instability present in ALT cells, they are able 
to progress through the cell cycle and continually proliferate.163 This suggests that ALT 
cells have employed mechanisms to deal with abnormal telomere capping.  
 Previous work in our lab demonstrated that TERRA is cell cycle regulated and 
coordinates the switch between RPA and POT1, a component of shelterin, at the 
telomere. However, recently we illustrated that cell cycle regulation of TERRA is 
disrupted in ALT cells, which sustain high levels of TERRA. High levels of TERRA 
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prevent the coordinated switch of POT1 with RPA. This prolonged loss of POT1 binding 
is an example of abnormal telomere capping. Additionally, this dysregulation of TERRA 
results in persistent RPA coated single stranded DNA (RPA–ssDNA), which promotes 
the formation of homologous recombination permissive structures. Therefore, ALT 
telomeres are primed for recombination, implicating altered regulation of TERRA as a 
potential initiating mechanism of ALT. TERRA is also a direct inhibitor of human 
telomerase in vitro.164 Therefore, TERRA’s role in the initiation of ALT could be two-
fold. First, TERRA could be responsible for promoting a recombinogenic prone 
telomeres, and second, TERRA could further promote ALT by inhibiting telomerase 
activity. Currently, there are not effective scientific methods for manipulating TERRA 
expression. Our lab is currently working on using CRISPR/CAS9 technology to alter 
TERRA expression. It would be interesting to determine if increased TERRA expression 
in pre-crisis primary fibroblasts results in activation of the ALT pathway.  Given that 
TERRA inhibits telomerase in vitro, it would be interesting to determine the outcome of 
increasing TERRA expression in telomerase positive cancer cells. It is possible that high 
levels of TERRA may repress telomerase activity sufficiently to induce cell death. 
Alternatively, telomerase positive cancer cells may adopt the ALT pathway in response 
to increased TERRA levels. Our data suggest the importance of further studying the role 
of TERRA in the activation of ALT.  
We also demonstrated that the chromatin remodeler ATRX represses TERRA. 
Loss of ATRX correlates with ALT status in cancers, suggesting a plausible mechanism 
for dysregulation of TERRA. It is hypothesized that changes in the chromatin may 
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facilitate ALT, and here we demonstrate that loss of the chromatin remodeler ATRX may 
promote ALT by allowing dysregulation of TERRA and persistent RPA at telomeres. 
Although based on our results it is likely that loss of ATRX plays an important role in 
ALT, loss of ATRX is not sufficient to induce ALT. Therefore, other factors that may 
work in concert with ATRX to drive ALT still need to be investigated.  
Almost all cancers, irrespective of tissue type, utilize mechanisms of telomere 
length maintenance. Conveniently, these mechanisms are not present in normal non-
cancer cells, making telomere maintenance mechanisms attractive therapeutic targets. In 
fact, telomerase inhibitors are currently in clinical trials.165 However, telomerase 
inhibitors are not likely to be effective in ALT positive cancers. Moreover, studies have 
demonstrated that inhibition of telomerase leads to the development of ALT phenotypes, 
suggesting ALT as a potential mechanism of resistance.166 Therefore, targeting both 
telomerase and ALT will be required to yield a successful therapeutic strategy.  
Currently, there are no ALT targeted therapies in clinical trials, owing primarily 
to the lack of basic research on targeting ALT cancers. We identified a novel therapeutic 
approach to the treatment of ALT positive cancers through inhibition of the DNA damage 
response kinase, ATR. We illustrated that inhibition of ATR results in disruption of ALT 
activity. Not only did ATR inhibition significantly reduce the presence of ALT associated 
PML bodies (APB), a key hallmark of ALT, but it also affected the recombinogenic state 
of ALT telomeres as seen through the decrease in telomeres sister chromatid exchange 
events (T-SCEs) and c-circles. Furthermore, we demonstrated that ATR inhibition 
selectively kills ALT positive cells. Importantly, the cells we tested were equally 
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sensitive to a panel of DNA damaging agents, ruling out the possibility that ALT cells are 
simply more susceptible to general damage. These studies provide a novel therapeutic 
avenue for treating ALT positive cancers.  
Despite providing a rational drug strategy for ALT cancers, our study has inherent 
limitations in translating our results to the clinic. Our results were obtained in cell culture, 
and in order to pursue ATR inhibition as a viable therapy, it will need to be tested in vivo. 
In efforts headed by Emily Mason-Osann, our lab is currently testing the efficacy of ATR 
inhibitors against ALT positive cancers in xenograft and patient derived xenograft 
models of osteosarcoma in mice. The preliminary results of this study are promising. We 
demonstrate that ATR is a critical regulator of the ALT pathway, however, the precise 
molecular mechanism of ATR’s role in ALT remains to be determined. Also, it would be 
beneficial to identify other factors required for ALT activity to develop comprehensive 
treatment options and aid in our knowledge of this complex pathway. 
 Given that ATR plays a critical role in both ALT and replication stress, it is likely 
that the management of replication stress is a key feature of the ALT pathway. Telomeres 
are considered to be common fragile sites because their repetitive nature presents a 
challenge to the replication machinery. This fragility is exacerbated at ALT telomeres 
due to a heightened frequency of non-canonical variant repeats. These variant repeats 
include the sequences TCAGGG, TTCGGG, and GTAGGG.69,70 The incorporation of 
these variants are sufficient to disrupt binding of TRF1 and TRF2 – shelterin components 
that bind with sequence specificity to the telomere. Not only are TRF1 and TRF2 
responsible for recruiting the remaining components of shelterin, but TRF1 loss increases 
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replication fork stalling. Therefore, ALT telomeres are particularly prone to replication 
stress. 
We hypothesized that the ALT pathway must rely on factors important in the 
resolution of replication stress. In fact, we demonstrate that the replication stress response 
protein SMARCAL1 is a key mediator of ALT activity. We demonstrate that 
SMARCAL1 associates exclusively with ALT telomeres to promote telomere stability in 
these cells. Furthermore, we illustrate that loss of SMARCAL1 leads to persistently 
stalled replication forks that collapse into DNA double strand breaks (DSBs). Recently, a 
study demonstrated that DSB formation was a key step in the initiation of RAD51-
dependent telomere clustering, which promotes the directed movement of ALT telomeres 
to PML bodies for telomere syntehsis.44 This mechanism explains how an ALT telomere 
can recombine with another ALT telomere that resides at a great distance. In support of 
this mechanism, we demonstrate that SMARCAL1 loss also promotes telomere 
clustering. Furthermore, depletion of RAD51 significantly reduced SMARCAL1 loss-
dependent telomere clustering, which suggested that our mechanism was also RAD51-
dependent. However, it is important to note that we only witnessed about a 75% 
reduction in telomere clustering. These results could be due to incomplete knockdown of 
RAD51 or temporal issues in reversing permanent clusters. These results also present the 
possibility of multiple telomere clustering mechanisms.  Alternatively, telomeres may 
recombine in ALT independent of clustering. Further investigation into mechanisms that 
allow ALT telomeres to identify potential homologous sequences for telomere synthesis 
will be beneficial in parsing out the ALT pathway.  
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Additionally, we demonstrated that loss of SMARCAL1 resulted in chromosome 
fusions and genetic instability in ALT cells but not in untransformed cells. The purpose 
of the RAD51-dependent telomere clustering mechanism proposed by Cho and 
colleagues is to drive telomeres together to facilitate HR mediated elongation.44 
However, with SMARCAL1 depletion, there is no telomere synthesis following RAD51-
dependent clustering. We hypothesize that the loss of SMARCAL1 imposes a burden of 
stress that ALT cells cannot handle. Therefore, instead of telomere synthesis, 
SMARCAL1 loss results in prolonged telomere clusters that go unresolved resulting in 
chromosome fusions. It is important to note that we did not observe telomere fusions in 
response to SMARCAL1 depletion in untransformed cells. We also did not detect the 
presence of SMARCAL1 at telomeres in untransformed cells, emphasizing the role of 
SMARCAL1 specifically in the ALT pathway. Given that SMARCAL1 is an important 
factor in the replication stress response in normal somatic cells, inhibiting SMARCAL1 
activity does not provide a viable therapeutic strategy for targeting ALT cancers. 
However, the recruitment mechanism of SMARCAL1 to telomeres could potentially be 
targeted. SMARCAL1 is recruited to stalled replication forks throughout the genome by 
RPA. However, the recruitment of SMARCAL1 to telomeres is independent of RPA.156 
Therefore, identifying the recruitment mechanism of SMARCAL1 to telomeres could 
provide a possible therapeutic strategy for targeting ALT positive cancers.  
ATR is a known regulator of both ALT and SMARCAL1 activity; it is plausible 
that ATR’s role in ALT may encompass SMARCAL1. We used the small molecule ATR 
inhibitor VE-821 to assess whether SMARCAL1 recruitment to ALT telomeres was 
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dependent on ATR. We saw no effect on SMARCAL1 localization to ALT telomeres 
with inhibition of ATR, but this does not negate the possibility of ATR involvement in 
regulating SMARCAL1 at telomeres. ATR plays many important roles in the cell, thus 
inhibiting ATR may not be a great method for testing specific effects on SMARCAL1. 
ATR is known to regulate SMARCAL1 by phosphorylating serine residue 652. 
Therefore, a better method for testing ATR regulation of SMARCAL1 would be to 
examine a SMARCAL1 phospho-mutant (S652A). This would also be useful in 
examining the effects of unregulated SMARCAL1 activity. It has been demonstrated that 
both overexpression and loss of SMARCAL1 are detrimental to the cell. Therefore, it 
would be interesting to investigate the effects of overactive SMARCAL1 in ALT cells.  
Ultimately, these studies highlight the paradoxical role of replication stress in the 
ALT pathway. Replication stress due to changes in chromatin structure at the telomere 
may promote the initiation and maintenance of ALT (Figure 5-1). However, if this 
replication stress is left unmanaged – for example through the loss of ATR activity or 
SMARCAL1 – ALT cells experience levels of genomic instability that they are ill 
equipped to handle.  
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Figure 5-1. Model of ALT activation and maintenance. Schematic depicting steps involved in the 
activation and maintenance of ALT. Data from the studies represented in this thesis are depicted in blue.  
 
 
. 
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